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ABSTRACT
Although mammalian lipocalin allergens are important respiratory sensitizers, little is known about the
immunological characteristics of these allergens, such as T-cell and B-cell cross-reactivity. The aims
of this study were to characterize the murine immune response to the bovine lipocalin allergen Bos d 2
and to elucidate T-cell and B-cell cross-reactivities among lipocalin allergens. Moreover, recombinant
dog allergens Can f 1 and Can f 2 were assessed to determine their suitability in diagnosing dog
allergy.
 Bos d 2, the major respiratory allergen of cow, is known to have a weak stimulatory capacity for
human peripherial-blood mononuclear cells. Here, the proliferative response to Bos d 2 was found to
be weak in six mouse strains with different major histocompatibility complex haplotypes. Futhermore,
only the BALB/c mouse mounted a distinct humoral response to Bos d 2. One immunodominant
epitope in Bos d 2, p127-142, was recognized by the BALB/c mouse. The response was of a T-helper
type 2. The localization of the epitope in Bos d 2 was similar to that recognized by human T cells. The
proliferative and cytokine responses to p127-142 also resembled those found with human T cells.
These results support the view that the allergenic capacity of Bos d 2 is associated with the response to
its immunodominant epitope.
 Human T cells have been shown to recognize a determinant in areas of the rat and dog major
allergens, Rat n 1 and Can f 1, corresponding to that of Bos d 2, p127-142. In the BALB/c mouse,
p127-142 did not exhibit T-cell cross-reactivity with the 11 lipocalin-derived peptides examined.
However, p127-142 did elicit a cross-reactive T-cell response with a bacterial peptide (SP7) from
Spiroplasma citri. The cytokine profile induced by SP7 differed from that induced by p127-142, since
the former was of a Th0 type. p127-142 and SP7 could reciprocally modulate in vitro the cytokine
response of the spleen cells primed by the other peptide. This result suggests that modified allergen
peptides can skew the phenotype of primed T cells. The phenomenon may open prospects for allergen
immunotherapy.
 The IgE cross-reactivity of mammalian lipocalin allergens is also poorly known. Four lipocalin
allergens and human tear lipocalin, showed IgE cross-reactivity. IgE inhibition experiments suggest
that both common and unique IgE epitopes are found between the IgE cross-reactive pairs (Can f 1
and TL; Can f 1 and Can f 2; Equ c 1 and Mus m 1). Since the sequence identity between the IgE
cross-reactive allergens varies from 23% to 61%, it can be speculated that cross-reactivity between
these allergens is more associated with their 3-dimensional structures than with the similarity of their
amino acid sequences. Furthermore, Can f 1 showed IgE cross-reacitivity with human tear lipocalin. It
is possible that IgE cross-reactivity among lipocalins, including endogenous lipocalins, may be
implicated in sensitization to lipocalin allergens.
 The recombinant dog allergens Can f 1 and Can f 2 were found to have high specificity (100%) for
the diagnostics of dog allergy. However, sensitivity analyzed by either skin prick tests, IgE
immunoblotting and enzyme-linked immunosorbent assay was weak. Immunoblot analyses suggested
that other allergens, in addition to Can f 1 and Can f 2, may also be important in sensitization to dog.
A 18 kDa protein in a commercial dog epithelial extract was recognized more frequently than Can f 1
by dog-allergic patients. The aminoterminal sequencing of the protein suggested that it is a new
member of the lipocalin family.
National Library of Medicine Classification: QW 504.5, QW 525.5, QW 570, QW 601, QW 900, QY 260
Medical Subject Headings: Allergens/immunology; Antibody Specificity/immunology; B-Lymphocytes;
Carrier Proteins/immunology; Cattle; Cytokines; Dogs; Enzyme-Linked Immunosorbent Assay; Epitopes;
Human; Hypersensitivity/immunology; Hypersensitivity/diagnosis; Immunoblotting; Immunoglobulin E;
Lipocalins; Receptors, IgE; Mice; Rats; Skin Tests; T-Lymphocytes/immunology
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ABBREVIATIONS
3-D 3-dimensional
Ag antigen
AE atopic eczema
AID activation–induced cytidine deaminase
AKC atopic keratoconjunctivitis
alum aluminium hydroxide
APC antigen-presenting cell
APRIL proliferation-inducing ligand
ARC allergic rhinoconjunctivitis
BLys B lymphocyte stimulator protein
CCD cross-reactive carbohydrate determinants
CCL chemokine ligand
CD cluster of differentiation
cDNA complementary deoxyribonucleic acid
CFA complete Freund's adjuvant
cpm count per minute
CTLA-4 cytotoxic T lymphocyte-associated antigen 4
DBPCFC double-blind placebo-controlled food challenge
DC dendritic cell
IDO indoleamine 2,3-dioxygenase
IEMA immuno-enzymometric assay
i.p. intraperitoneally
ELISA enzyme-linked immunosorbent assay
ELISPOT enzyme-linked immunospot assay
Fc?RI high affinity receptor for immunoglobulin E
FEIA fluoroenzyme-immunometric assay
FOXP3 forkhead/winged helix family transcription factor -3
GM-CSF granulocyte magrophage-colony stimulating factor
HEL hen egg lysozyme
HPLC high–pressure liquid chromatography
IC50 concentration required for 50% inhibition
IFA incomplete Freund's adjuvant
IFN interferon
Ig immunoglobulin
IL interleukin
ISAAC International Study of Asthma and Allergies in Childhood
IUIS International Union of Immunogical Societies
kDa kilodalton
mAb monoclonal antibody
MHC major histocompatibility complex
MnSOD manganese superoxide dismutase
MS multiple sclerosis
n natural
NFAT nuclear factor of activated T cells
nsLTP nonspecific lipid-transfer protein
p127-142 peptide 127-142 of Bos d 2
PAC perennial allergic conjunctivitis
PAMP pathogen-associated molecular pattern
PAR protease-activated receptor
PBMC peripheral-blood mononuclear cell
PBS phosphate-buffered saline
PD-1 programmed death-1
PGE2 prostaglandin E2
PRR pattern recognition receptor
r recombinant
RAST radioallergosorbent test
RNA ribonucleic acid
SAC seasonal allergic conjunctivitis
s.c. subcutaneously
SDS-PAGE sodium dodecylsulphate-polyacrylamide gel electroforesis
SEM standard error of mean
SI stimulation index
SP database search peptide
SP7 database search peptide from Spiroplasma citri
SPT skin prick test
SOCS1 supressor of cytokine signaling–1
TCR T-cell receptor
TGF transforming growth factor
Th cell T-helper lymphocyte
TL tear lipocalin, von Ebner's gland protein, VEGP
TLR Toll-like reseptor
Treg cell regulatory T lymphocyte
TT tetanus toxoid
VKC vernal keratoconjunctivitis
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1. INTRODUCTION
In recent decades, the prevalence of allergic diseases and asthma has increased considerably
in Finland (Huurre et al., 2004; Isolauri et al., 2004) as well as in other developed countries
(Asher et al., 2006). The ISAAC study published in 2006 showed that the prevalence of
asthma symptoms in Finnish children aged 13-14 years had increased from 13.1% to 19.0%
within five years (Asher et al., 2006). Despite intense study, the mechanisms of allergic
diseases are still not fully understood.
 Most major, as well as several minor, mammalian respiratory allergens belong to the
family of lipocalin proteins. The lipocalins are proteins that can act, for example, as
transporters of small hydrophobic molecules (Flower, 1996), modulators of cell growth, and
regulators of immune response (Åkerström et al., 2000; Lögdberg et al., 2000). The lipocalin
allergens include the major allergens of dog, horse, mouse, rat and, cow (Virtanen et al.,
2004). The major allergen of cat, Fel d 1, is a unique allergen among animal-derived
respiratory allergens in that it is not a lipocalin (Kaiser et al., 2003). The lipocalins are present
both in animals and humans (Åkerström et al., 2000).
 Despite the fact that IgE cross-reactivity among pollen and food allergens is common and
widely studied (Radauer et al., 2006a), the cross-reactivity among animal allergens is poorly
known. For example, few cross-reactivity studies have focused on animal-derived lipocalin
allergens (Fahlbusch et al., 2003; Kamata et al., 2007). In addition to IgE cross-reactivities
between allergens, the IgE cross-reactivities between endogenous proteins and environmental
allergens have also been reported (Budde et al., 2002; Aichberger et al., 2005; Limacher et al.,
2007).
 IgE cross-reactivity has many potential impacts on allergy. For example, IgE cross-reactive
allergens can cause clinical symptoms in patients without prior sensitization (Wensing et al.,
2002; Bohle et al., 2003) or lead to misdiagnosis of related allergens (Kochuyt et al., 2005).
On the other hand, IgE cross-reactivity between allergens can be useful in the diagnostics of
multivalent sensitizations (Tinghino et al., 2002) and immunotherapy of allergy (Niederberger
et al., 1998). Moreover, it has been proposed that IgE cross-reactive proteins, especially
endogenous proteins that are IgE cross-reactive with exogenous allergens, may be involved in
regulating or tolerizing an allergic response (Aalberse et al., 2001), for example, through the
high affinity IgE receptor (Fc?RI) and  indoleamine 2,3-dioxygenase (IDO) (von Bubnoff et
al., 2003).
18
 T-cell cross-reactivity is strikingly different from IgE cross-reactivity and much more
difficult to predict (Aalberse, 2005). T-cell cross-reactivity between pollen allergens Cha o 1
and Cry j 1 has been shown to contribute to prolonged symptoms even after the pollen
seasons of these trees (Sone et al., 2005). Moreover, the activation of pollen-specific Th2 cells
by related food allergens, in particular outside the pollen season, may cause deterioration of
atopic eczema without a clinical food allergy (Bohle, 2007). Several studies have
demonstrated that exogenous allergens can show T-cell cross-reactivity with endogenous
counterparts (Fluckiger et al., 2002; Aichberger et al., 2005). It has been further suggested
that environmental allergens mimicking a self antigen may represent an important
pathomechanism involved in the maintenance and exacerbation of severe forms of allergy
(Bünder et al., 2004).
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2. REVIEW OF THE LITERATURE
2.1 Allergic diseases
2.1.1 General
Atopy and asthma prevalences have increased in the developed countries (Vartiainen et al.,
2002). For example, it has been estimated that among adults 24-30 % suffer from allergic
rhinitis, 5-8% from asthma, and 10-20% from atopic eczema in Finland (Huurre et al., 2004;
Haahtela et al., 2007). Moreover, the birth cohort study of Isolauri et al. showed that the
proportion of subjects with detectable IgE antibodies against aeroallergens had consistently
increased over the period from 1923-26 to 1990 (Isolauri et al., 2004). In addition to the
adverse health effects for the patients, allergic diseases can also pose a significant economic
burden. The immediate costs of allergy and asthma were estimated to be as high as 380
million euros in 2001 (http://www.terveyskirjasto.fi/terveyskirjasto/tk.koti?p_artikkeli
=suo00033).
 Hypersensitivity is a term used to describe objectively reproducible symptoms or signs
initiated by exposure to a defined stimulant at a dose tolerated by normal persons (Johansson
et al., 2004). Allergy is defined to be a harmful antibody or cell-mediated immune reaction
against innocuous antigens, allergens, commonly present in the environment (Johansson et al.,
2004). Atopy is a personal and/or familial tendency, usually in childhood or adolescence, to
become sensitized and to produce IgE antibodies on exposure to innocuous antigens. As a
concequence, atopic persons can develop typical symptoms of asthma, rhinoconjunctivitis, or
eczema (Johansson et al., 2004). Although atopic diseases have a genetic background, several
results suggest that atopic disposition may also be related to differences in lifestyle and
environmental factors (von Mutius et al., 1998; Vartiainen et al., 2002; Asher et al., 2006) .
2.1.2 Allergic diseases
One of the most common allergic disease is allergic rhinitis. According to a study by Huurre
et al., 26% of 32-year-old adults suffer from allergic rhinitis in Finland (Huurre et al., 2004).
The early-phase symptoms, itching, sneezing and watery rhinorrhea, are mainly caused by the
release of inflammatory mediators of mast cells, of which histamine is the most important
(Prussin et al., 2003). The immunological process in both nasal and bronchial tissue involve
Th2 lymphocytes and eosinophils (Gelfand, 2004). Moreover, other cell populations, such as
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dendritic cells and mast cells, have also been shown to be involved in this process
(Rosenwasser, 2007). During the late phase reaction, T cells and mast cells release cytokines,
such as IL-4 and IL-5, which stimulate IgE production in B cells and also activate
eosinophils. The symptoms of chronic ongoing rhinitis, such as the nasal blockage, loss of
smell and “nasal hyper-reactivity”, are due to eosinophils (Gelfand, 2004).
  The term allergic conjunctivitis subsumes several types of conjunctivitis, such as seasonal
allergic conjunctivitis (SAC) (Bonini, 2004). Patients with allergic conjunctivitis often have a
personal or family history of atopy. When accompanied by allergic rhinitis, allergic
conjunctivitis is called allergic rhinoconjunctivitis (ARC). Approximately 15% of the children
aged 13-14 years suffer from ARC in Finland (Asher et al., 2006). Especially, in atopic and
vernal keratoconjunctivitis, clinical sensitizations to common allergens cannot be detected
using skin prick tests or IgE immunoassays (Bonini, 2004; Pucci et al., 2003).
 The classical type 1 immediate hypersensitivity mechanism (mast cell degranulation
induced by the allergen-IgE interaction) is not sufficient to explain all the pathophysiological
abnormalities in allergic conjunctivitis (Bonini, 2004). The Th2-type inflammation with mast
cells, basophils, eosinophils and polyclonal IgE activation is suggested to have an important
role in these disorders (Romagnani, 1994).
 The International Study of Asthma and Allergies in Childhood (ISAAC) showed that the
prevalence of asthma in children aged 13-14 years was 5-20% in most countries (Asher et al.,
2006). Asthma is a chronic inflammatory disease of the bronchial airways with an increased
number of activated T cells, eosinophils, mast cells and neutrophils within the airway lumen
and bronchial submucosa (Hamid et al., 2003; Marone et al., 2005). Those patients
susceptible to asthma often have symptoms associated with inflammation, ranging from
bronchial hyperresponsiveness to a variety of inhaled bronchoconstrictor stimuli (Gounni et
al., 2005).
 Asthma can be classified as either allergic or nonallergic asthma. Most cases of asthma in
children (80%) and in adults (>50%) have been reported to be allergic and mainly IgE-
associated (Johansson et al., 2004). Serum IgE plays an important role in the pathogenesis of
smooth muscle hyperreactivity. Recently, human airway smooth muscle (HASM) cells were
found to express FceRI-receptor. IgE sensitization of the cultured cells induced the release of
inflammantory mediators, including Th2-type of cytokines IL-5 and IL-13, and chemokines
(Gounni et al., 2005).
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 Eczema, formerly also known as atopic dermatitis or atopic eczema, is an inflammantory,
clinically relapsing, noncontagious, and extremely pruritic hereditary skin disease (Allam et
al., 2005). Recently, the term ‘atopic eczema’ was defined more precisely to be used only for
skin reactions based on IgE sensitization proven by allergen-specific IgE assays and /or skin
prick test (Johansson et al., 2004). Atopic eczema is one of the most commonly seen
dermatoses, with a prevalence of 22% in children and 13% in young adults in Sweden (Asher
et al., 2006). The disease often begins in early childhood (after 3 months of life) and typically
affects the face, extensor sides of arms, or legs. The clinical signs of AD may precede the
development of asthma and allergic rhinitis, suggesting that AD forms an "entry point" for
subsequent allergic disease (Spergel et al., 2003). Eczema is exacerbated by food allergies,
especially severe forms of AE in children (Novak et al., 2003). Atopic eczema is
characterized by blood eosinophilia and increased IgE production (Breuer et al., 2001). The
dominance of Th2-type cells is typically associated with acute-phase skin lesions, whereas
chronic-phase lesions also contain Th1 cells (Allam et al., 2005). It has been speculated that
cytokines derived from Th2-type cells present in the early phase of atopic eczema may attract
eosinophils, stimulate IL-12 expression and thereby cause sequential activation of Th0 and
Th1-type cells (Grewe et al., 1998). Furthermore, FceRI-bearing Langerhans cells and
plasmacyoid dendritic cells have an important role in the pathophysiology of AE (Novak et
al., 2004; Allam et al., 2005).
 Apart from other dermatoses, such as dermatitis, urticaria and angioedema, allergic
diseases can also include food and drug allergies. Dermatitis and urticarias are caused by a
wide variety of agents, including drugs, food allergens, infections, or systemic diseases
(Zuberbier et al., 2007). The mechanisms underlying dermatoses, food and drug allergies, can
be mediated by immunological and nonimmunological mechanisms (Johansson et al., 2004;
Hennino et al., 2006).
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2.2 Allergic sensitization
2.2.1 Cells of the immune system involved in sensitization
2.2.1.1 Antigen-presenting cells
Antigen-presenting cells (APC) are a group of cells, including dendritic cells (DC),
monocytes/macrophages and B cells, that can uptake antigens and present them to T
lymphocytes via major histocompatibility complex (MHC) I and MHC II molecules
(Peppelenbosch et al., 2000; Burgdorf et al., 2007). Moreover, eosinophils can act as APCs
and polarize T cells into a Th2 subset in a manner similar to that of DC (Padigel et al., 2006).
 DCs are a group of migratory bone-marrow-derived leukocytes that specialize in the
uptake, transport, processing and presentation of antigens to T cells (Shortman et al., 2002).
DCs are essential for CD4+ T-cell priming and for T-cell differentation (Eisenbarth et al.,
2003). DCs circulate and capture antigens at an immature state in peripheral tissues, such as
the skin, the lung and the gut (Wilson et al., 2003). Antigen uptake with the presence of
pathogen-associated molecular patterns (PAMPs) (Kapsenberg, 2003) or signals from
damaged tissues, e.g., heat-shock proteins, leads to the maturation and migration of DCs to
lymph nodes where they are able to stimulate naïve T cells (Shortman et al., 2002). Moreover,
DC subsets are found to express distinct patterns of Toll-like receptors (Eisenbarth et al.,
2003), such as TLR2 and TLR9, which are important in the polarization of T-cell phenotypes
(Redecke et al., 2004). In mucosa, DCs have an immature phenotype and are capable of
uptaking and processing allergen, though they lack the capability to stimulate naïve T cells
(van Rijt et al., 2005).
2.2.1.2  T-helper cells
The major class of T cells is defined by its surface expression of the ab T-cell receptor, the
antigen receptor of the T cell. The major task of CD8+ T cells is to kill cells infected by
intracellular microbes. The CD4+ T cells regulate the cellular and humoral (B-cell help)
immune responses and are therefore important cells in allergy. They are divided into several
different subtypes (Fig.1). In the blood and secondary lymphoid organs, approximately 65%
of T cells are T-helper cells (Th cells) (Chaplin, 2003). T cells undergo maturation in thymus.
Fewer than 5% of the developing T cells survive positive and negative selection of the
maturation and migrate to the periphery (Chaplin, 2003).
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Figure 1. CD4+ T-cell phenotypes in allergy. Reprinted from J Allergy Clin Immunol, vol:120,
Schmidt-Weber CB, Akdis M ,Akdis CA., TH17 cells in the big picture of immunology. p. 247-54,
copyright 2007, with the permission from Elsevier
 T-helper cells are further polarized into a Th1 or Th2 phenotype during the immune
response. It has been suggested that several surface markers, such as TIM-1, TIM-2 and
CD62L, can differentiate Th1 cells from Th2 cells. For example, Th1 cells are found to
express TIM-3 (Monney et al., 2002) while Th2 cells express TIM-2 (Chakravarti et al.,
2005) and CD62L (Matsuzaki et al., 2005). Th1 cells secrete, for example, IL-2, IFN-g and
TNF-b following activation. They are involved in the induction of inflammatory reactions that
are often accompanied by tissue damage and destruction (Yssel et al., 2001). However, Th1
cells may also contribute to the chronicity and effector phase in allergic diseases, such as
asthma (Taylor et al., 2005). Th2 cells are involved in parasite infections and allergy, and
provide optimal help for humoral immune responses, including the class switching of B cells.
Moreover, the Th2 cell-produced cytokines IL-4, IL-5, and IL-13 mediate regulatory and
effector functions, such as prolonged eosinophil survival and recruitment, as well as tissue
homing of Th2 cells (Ying et al., 1997; Romagnani, 2004). Other cytokines secreted by Th2
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cells include IL-9, IL-10, and the granulocyte magrophage-colony stimulating factor (GM-
CSF) (van Rijt et al., 2005). Furthermore, T cells capable of producing mixed patterns of Th1
and Th2 cytokines are classified as Th0 cells (Abbas et al., 1996). The recently found Th17
cells form a new subset of T-helper cells. They secrete cytokines, such as IL-17 and IL-6.
The role of Th17 cells in allergy is largely unclear but experimental models suggest that IL-17
may be important for neutrophilic recruitment in the acute airway inflammation (Fujiwara et
al., 2007) and in the initiation of asthma (Schyder-Candrian et al., 2007).
2.2.1.2  Regulatory T cells
 Regulatory T cells (Treg cells), previously also referred to as suppressor T cells, include
cell populations of several types (Curotto de Lafaille et al., 2002; Akdis et al., 2004). The
main subsets of regulatory cells are CD4+ CD25+ Treg cells and type 1 regulatory T cells
(Tr1) (Bacchetta et al., 2005). However, additional regulatory T cells, such as Th3 cells and
other cell types with regulatory function, have been reported (Taylor et al., 2005). The
regulatory T cells can suppress both Th1 and Th2 cells through multiple mechanisms. These
suppressive mechanisms include secretion of immunosuppressive cytokines (e.g., IL-10 and
TGF-?) (Akdis et al., 1998; Akdis et al., 2004), and expression of surface molecules (CTLA-4
(cytotoxic T lymphocyte-associated antigen 4) (Read et al., 2000) and PD-1 (programmed
death-1) (Nishimura et al., 1999)). It has been shown that CD4+CD25+ T cells and IL-10
have important roles in specific immunotherapy (Akdis et al., 1998; Savolainen et al., 2004)
and in healthy immune response (Jutel et al., 2003).
 The natural regulatory T cells (nTreg) develop in the thymus. They express CD4 and CD25
molecules on their surfaces, as well as a forkhead/winged helix transcription factor FoxP3
(Rouse, 2007). nTreg cells contribute to the maintenance of immunological self-tolerance and
immune homeostasis (Miyara et al., 2007). The suppressive function of nTreg cells is mainly
based on cell contact-dependent interactions (Bacchetta et al., 2005). Especially surface
molecules, such as CTLA-4, have a central role in the suppressive mechanism of
CD4+CD25+ FoxP3 Treg cells (Miyara et al., 2007). It was recently observed  that
CD4+CD25+ T cells from non-atopic donors suppressed the proliferation and cytokine
production of allergen-stimulated CD4+CD25- T cells whereas the inhibition was diminished
with the CD4+CD25+ T cells from atopic patients and patients with hayfever (Ling et al.,
2004)
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 Tr1 cells regulate immune responses in transplantation, allergy, and autoimmune diseases
(Bacchetta et al., 2005). The suppressive effects of both Tr1 and Th3 cells are based on the
high production of immunosuppressive cytokines (Taylor et al., 2005). The major effector
cytokine in Tr1 cells is IL-10 and to a smaller degree TGF-? (Rouse, 2007). Th3 cells, on the
other hand, produce high amounts of TGF-? and variable amounts of IL-10 and IL-4 (Chen et
al., 1994).
2.2.1.4 B cells
B cells are pivotal in the adaptive immune response in that they provide humoral immunity
through their secreted antibodies. B cells express the CD19 molecule on their surface and
constitute approximately 15% (range 5-21%) of the peripheral-blood lymphocytes (Jentsch-
Ullrich et al., 2005). B cells are divided into memory and plasma cells. The latter are
terminally differentiated antibody-producing cells. Traditionally, plasma cells have been
considered short-lived, end-stage lines of B-cell differentiation. However, recent studies have
shown that plasma cells can survive long periods in appropriate survival niches (Radbruch et
al., 2006). Furthermore, the development of B-cell memory is thought to be critical in
exacerbating allergic syndromes (Chaplin, 2003). It has been suggested that long-lasting IgE
responses in both mice and humans are due to long-lived plasma cells (Aalberse et al., 2004;
Radbruch et al., 2006), since specific IgE levels may remain high or even rise, despite
successful allergen immunotherapy (Kinaciyan et al., 2007).
 Because B cells are able to internalize soluble antigens, they can serve as antigen-
presenting cells for T cells. B cells capture their cognate antigen, process it intracellularily,
and present the peptides on the cell surface associated with MHC class II molecules (Chaplin,
2003). B cells can be activated in a T cell-dependent and T cell-independent manner. T-helper
cells that recognize the peptide:MHC complex deliver activating signals to the B cells. One
particulary important co-stimulatory molecule in B-cell activation is the T-cell surface
molecule CD40L. In contrast to T cell-dependent activation, in which monomeric antigens
activate the B cells, T cell-independent activation requires polymeric antigens, such as
bacterial lipopolysaccharide, to activate B cells. This activation may occur through the cross-
linking and clustering of Ig molecules on the B-cell surface.
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2.2.2 Development of the Th2-deviated cellular immune response
2.2.2.1 Allergic sensitization
An allergic reaction requires prior immunization, known as sensitization, to the allergen (Fig.
2). Initial contact with a soluble allergen on mucosal surfaces favors allergen uptake by the
potent APC. In the case of respiratory allergies, contact with minute amounts of intact,
soluble allergens takes place at the mucosal surface of respiratory tract (Valenta, 2002). The
interaction with APCs, such as dendritic cells, initiates the T-cell response and differentation.
Furthermore, sensitization leads to the establishement of allergen-specific, long-lived memory
T cells (Chakir et al., 2000). The T cell-B cell interaction in the presence of IL-4 and IL-13
promotes the IgE-class switch (Plebani, 2003). Subsequent allergen contact of B cells in the
presence of T-cell help will boost IgE memory B cells to produce increased levels of allergen-
specific IgE antibodies (Valenta, 2002).
 Although Th2 cells are important in allergic sensitization, the Th1 or mixed Th1/Th2
profile is associated with severe forms of chronic allergic diseases, such as asthma (Bünder et
al., 2004) and atopic dermatitis (Aichberger et al., 2005) .
Figure 2. Allergic sensitization. Reprinted by permission from Macmillan Publisher Ltd: Nat
Rev Immunol, vol:2, Valenta R. The future of antigen-specific immunotherapy of allergy, p.446-5,
copyright (2002).
27
2.2.2.2 Polarization of the cellular immune response
Factors including the route of antigen exposure, the type of antigen-presenting cells, the
cytokine milieu at the site of challenge, and the dose of the antigen are all believed to
influence the development of T-helper cell phenotypes (McKenzie et al., 1998b). Although
dendritic cells have an important role in T-cell polarization, it is becoming evident that
several cell types, such as mast cells, basophils and eosinophils, are important in T-cell subset
development, as well (Prussin et al., 2003; Adamko et al., 2005; Galli et al., 2005a; Galli et
al., 2005b; Gibbs, 2005).
2.2.2.2.1 Cytokines
The key regulator of Th2 polarization seems to be the so-called “early” interleukin-4 (IL-4)
(Haas et al., 1999). For example, IL-4-knockout mice do not develop an allergic inflammatory
response after airway challenge (Herrick et al., 2003). Although predominantly produced by
basophils (Prussin et al., 2003; Gibbs, 2005), IL-4 can also be produced by mast cells
(Saarinen et al., 2001; Robinson, 2004; Galli et al., 2005a), eosinophils (Adamko et al., 2005),
natural killer T cells, and Th2 cells (Valenta, 2002). Ligation of IL-4R by IL-4 results in the
activation of the Janus family of tyrosine kinases and STAT6 activation, which has a central
role in the gene regulation of Th2 differentation. Moreover, STAT6 activation results in the
upregulated expression of the Th2 specific transcription factor GATA-3, which may further
upregulate the expression of several Th2 cytokines (Haas et al., 1999; Yoshimoto et al.,
2007).
Apart from IL-4, additional cytokines, such as IL-6, IL-13 and IL-18 may favor Th2 cell
polarization (Haas et al., 1999). Interleukin-13 can elicit responses in T cells similar to those
in IL-4. McKenzie et al. showed that IL-13-deficient mice produced significantly reduced
levels of IL-4, IL-5, and IL-10 and of serum IgE (McKenzie et al., 1998b). Thus, it seems that
IL-13 performs a central regulatory role in the development of Th2 cells (McKenzie et al.,
1998a; Scales et al., 2007). IL-18 is secreted by activated macrophages (Dai et al., 2007).
Although the major action of IL-18 is induction of IFN-g by Th1 cells, it was shown that IL-
18 causes IL-4-dependent Th2 polarization in vitro (Yoshimoto et al., 2000; Shida et al.,
2001) . However, IL-18 in combination with IL-12 polarizes the response towards Th1-type
(Li et al., 2005).
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 IL-6 is a cytokine produced by a number of cell types, including antigen-presenting cells
(magrophages, DCs, and B cells), fibroblasts, Th2 cells, and endothelial cells (Mowen et al.,
2004). IL-6 is a proinflammatory cytokine that, for example, activates endothelial cells
(Romano et al., 1997) and induces the synthesis of acute phase proteins (Xing et al., 1998). It
elicits Th2 differentation in two independent molecular mechanisms (Diehl et al., 2002). IL-6
promotes Th2 differentation by activating transcription through the nuclear factor of activated
T cells (NFAT), thus leading to production of IL-4 by naïve CD4+ T cells (Diehl et al., 2002).
Moreover, IL-6 inhibits Th1 differentation by inducing SOCS1 (supressor of cytokine
signaling–1) expression, which interferes with IFN-g signaling (Diehl et al., 2000).
Nevertheless, it seems that IL-6 is not essential for Th2 development (Blum et al., 1998; La
Flamme et al., 1999).
 Th2 polarization can be favored by the inhibition of Th1 polarization. Recently, Traidl-
Hoffmann et al. have shown that inhibition of IL-12, the important interleukin for Th1
differentation, enhanced Th2 polarization (Traidl-Hoffmann et al., 2005). In parasitic
infections, IL-4 (Yamakami et al., 2002) and IL-10 can suppress IL-12 production and Th1
response development, thereby ensuring Th2 polarization (Yamakami et al., 2002; McKee et
al., 2004).
2.2.2.2.2 Role of antigen-presenting cells
Dendritic cells (DCs) are essential in CD4+T-cell priming and T-cell differentation
(Eisenbarth et al., 2003). Contrary to what had been previously thought, the Th1/Th2
sensitizations induced by myeloid and plasmacytoid DCs are not confined to one subset
(Cabanas et al., 2000; Shortman et al., 2002; van Rijt et al., 2005). The maturation of DCs
represents a key regulatory step in T-cell activation and polarization (Eisenbarth et al., 2003;
van Rijt et al., 2005). Maturation of DCs mainly relies on recognition of pathogen-associated
molecular patterns (PAMPs) by Toll-like receptors (TLRs) belonging to the group of pattern
recognition receptors (PRRs) (Kapsenberg, 2003). Furthermore, TLR2 seems to be important
in Th2 deviation, whereas TLR9 is important in Th1 deviation (Redecke et al., 2004). The
maturation of DCs induces their migration to draining lymph nodes. Without this migration of
DCs, the Th2 sensitization to inhaled allergens can not occur (Eisenbarth et al., 2003). The
recognition of PAMPs was thought to be involved only in Th1 responses. However, it seems
that they have a role in inducing Th2 responses, as well. It has been observed that without a
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PAMP protein, allergens do not activate APCs in vivo nor in vitro, but instead further induce
Th2 sensitization (Eisenbarth et al., 2003).
 Polarization of T-helper cells requires three dendritic cell-derived signals. The first signal
is the antigen-specific signal mediated through the MHC class II/peptide complex coupled
with TCR. The production of Th2 cytokines up-regulate MHC II expression on APCs, which
reciprocally stimulate Th2 cells, favoring a Th2 disease pathway due to selective down-
regulation of IL-12 (Powe et al., 2004). The second, co-stimulatory signal is mainly mediated
by the triggering of CD28 by CD80 and CD86 (Kapsenberg, 2003). Induction of the Th2
response also involves other important co-stimulatory signals, such as OX40/OX40L
(Hoshino et al., 2003) and CD40/CD40L (MacDonald et al., 2002). The absence of a co-
stimulatory signal leads to anergy and possibly to tolerance (Kapsenberg, 2003). The
recognition of PAMPs by DCs mediates the third signal, in addition to signals 1 and 2 (van
Rijt et al., 2005). The activation of particular PRR by PAMPs defines the profile of T cell-
polarizing factors (Kapsenberg, 2003). Furthermore, Th2 polarization can be influenced by
CCL2 (chemokine licand), PGE2 (prostaglandin E2), and histamin via polarizing dedritic cells
(Kapsenberg, 2003).
 In addition to denritic cells, other cells such as eosinophils are also known to affect the
polarization of Th2 cells. Eosinophils express co-stimulatory molecules essential for
interaction with lymphocytes (Adamko et al., 2005).
2.2.2.2.3 Role of the antigen
Much experimental research has demonstrated that Th2 priming is preferentially favored by
low-dose antigen exposure, whereas higher doses favor Th1 development (Holt et al., 2005).
The nature of the antigen can also instruct DCs to influence the polarization of T cells (van
Rijt et al., 2005). For example, the eggs rather than the worms of Schistosoma mansoni induce
the maturation of DCs into a subtype which promotes the development of the Th2 phenotype
(Kapsenberg, 2003). Moreover, Aspergillus fumigatus conidae induce a Th1 type of response,
whereas the hyphae cause a Th2 response (Bozza et al., 2002). Anderson et al. showed that
birch allergens have an intrinsic Th2-polarizing ability on neonatal cells by suppressing DC
maturation (Andersson et al., 2004). The characteristics of the antigen are discussed below in
more detail.
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2.2.3 Immediate allergic reaction
2.2.3.1 Synthesis of immunoglobulin E (IgE)
IgE class-switch recombination is accomplished through 2 pathways (Geha et al., 2003). The
classical or T cell-dependent pathway of IgE synthesis involves the presence of IL-4, IL-13,
or both during ligation of the CD40-CD40 ligand. The ligation leads to the induction of Ce
germline transcription and of activation–induced cytidine deaminase (AID) (Poole et al.,
2005). The second pathway requires no T-cell interaction but does require IL-4. The T cell-
independent IgE class-switch takes place when the B lymphocyte stimulator protein (BLys)
and the proliferation-inducing ligand (APRIL), both expressed on monocytes and dendritic
cells, bind to their respective receptors on the B cells in the presence of IL-4 (Litinskiy et al.,
2002). Moreover, it has been shown recently that IgE synthesis can be induced by IL-4 and
IL-13, which are produced by adenosine-activated mast cells (Ryzhov et al., 2004). Since IL-
4 and CD40L are also expressed by basophils, the role of basophils in IgE class-switch has
been discussed as well (Prussin et al., 2003). IgE class-switch, on the other hand, is negatively
regulated by several mechanisms, including cytokines (e.g., IFN-? and IL-21), various B-cell
surface receptors (CD45, CD23), and several transcription factors (Poole et al., 2005).
2.2.3.2 Type I hypersensitivity
Mast cells and basophils have been regarded as key effector cells in IgE-associated immediate
hypersensitivity and allergic disorders (Galli et al., 2005a). Atopic diseases are also
classically associated with eosinophilia (Adamko et al., 2005). Release of mediators by mast
cells and basophils, as well as by eosinophils, begins within minutes of antigen challenge in a
sensitized individual. In such individuals, preformed IgE specific for the allergen is bound on
the surface of the effector cells by the type I high-affinity Fc-receptor of IgE (Fc?RI). The
cross-linking of the FceRI requires that an allergen binds to at least two antibody molecules
on the surface of the effector cell. Therefore, for antibody binding to occur, an allergen must
contain at least two IgE binding sites (epitopes), each of which will be a minimum of
approximately 15 amino acid residues in length. Antibody cross-linking of FceRI on effector
cells elicits changes in the cell membrane, causing degranulation. Release of mediators, such
as histamin, leukotrienes and prostaglandins, increases vascular permeability, smooth muscle
contraction, tissue edema and excretion of mucus. The pattern of the mediators depends on
the signal, activation site and cytokine milieu. Activation of effector cells also leads to
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cytokine secretion. For example, after allergen challenge, basophils are the predominant IL-4-
producing cells in the human asthmatic airways (Prussin et al., 2003). On the other hand, in
the upper dermis of lesional atopic dermatitis skin mast cells are one of the major sources of
IL-4 (Saarinen et al., 2001). Recently, it has become apparent that effector cells, like mast
cells and basophils, are active in maintaining a state of inflammation (Powe et al., 2004).
2.3 Allergens
2.3.1 General
Despite several attempts to find out, it seems that allergens do not have one single unifying
structural or functional feature (Aalberse, 2000; Radauer et al., 2006a). The properties of
protein structure most likely to be relevant for allergenicity are solubility, stability, size, and
the compactness of the overall fold. For airborne allergens, size and solubility are important
(Aalberse, 2000).
 In addition to structural characteristics, it is believed that the functional characteristics of
some allergens may also play a role in sensitization. Proteins such as lipocalins, nonspecific
lipid-transfer proteins (nsLTPs) and calcium-binding proteins show increased stability and
resistance to proteolysis (Breiteneder et al., 2005). Moreover, increased thermal stability and
stability to digestion have been claimed as characteristics of some food allergens (van Ree,
2002), e.g., for peanut allergen Ara h 1 (Maleki et al., 2000).
 Several allergens, such as Api m 1, Equ c 1, Equ c 4 and Equ c 5, have surfactant
properties. Hydrophobic interactions may take place when proteins come into contact with
membrane phospholipids or hydrophopic surfaces, such as a pulmonary surface, favoring
allergen penetration into the tissue (Goubran Botros et al., 2001). It has recently been
suggested that a common denominator for allergens would be the lack of bacterial homologs
(Emanuelsson et al., 2007).
 The allergenicity of respiratory animal lipocalins is hypothesized as arising from the
similarity between exogenous allergens and endogenous lipocalins (Virtanen et al., 1999). It
seems that T-cell epitopes in lipocalin allergens are clustered in a few regions along the
molecules (Zeiler et al., 1999; Jeal et al., 2004; Immonen et al., 2007). Furthermore,
experimental data and epitope predictions suggest that endogenous lipocalins and allergenic
lipocalin allergens may have T-cell epitopes in the corresponding parts of the molecule (Zeiler
et al., 1999; Immonen et al., 2005). Therefore, it can be further speculated that T-cell
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reactivity against lipocalin allergens may be modified by endogenous lipocalins, for instance,
by preventing strong T-cell reactivity against lipocalin allergens (Virtanen et al., 1999). Weak
T-cell reactivity is known to favour Th2-type responses (Pfeiffer et al., 1995; Janssen et al.,
2000; Foucras et al., 2002). Furthermore, the IgE cross-reactivity between the major dog
allergen Can f 1 and human tear lipocalin is also in line with this hypothesis (Saarelainen et
al., 2007).
 Antibody response to pollen, arthropod or fungal allergens appears to differ from that of
animal allergens (Platts-Mills, 2007). For example, the specific IgE titers of mite allergens
can be very high, whereas specific IgE titers to animal allergens are generally low (Erwin et
al., 2007; Reininger et al., 2007). Recently, it has been suggested that one reason for the
difference in antibody response between arthropod and animal allergens may be the
methylation of DNA associated with the allergens (Platts-Mills, 2007). Unmethylated DNA,
such as DNA of mite (Platts-Mills, 2007), contains immunostimulatory sequence motifs that
are reconized by TLR9 (Horner, 2006).
2.3.2 Posttranslational modifications
Posttranslational modifications, such as intramolecular disulfide bonds and glycosylation,
have been proposed to enhance the allergenicity of a protein by increasing its uptake and
detection by the immune system (Huby et al., 2000). Deletion of disulfide bonds from Asp f 2
has been shown to reduce the binding of IgE from allergic patients (Banerjee et al., 2002).
However, intramolecular disulfide bonds per se do not make a protein an allergen, nor does
their absence preclude allergenicity (Huby et al., 2000).
 Since many allergens, especially in the plant kindom, are glycosylated it is possible that the
glycosyl groups could contribute to their allergenicity. It is clear that IgE binds to N- and O-
linked oligosaccharides, especially N-glycans with 1-3 linked fucose and b1-2 linked xylose,
in plant and invertebrata allergens (Wilson et al., 1998; van Ree et al., 2000; Fotisch et al.,
2001) and can activate basophils  (Bublin et al., 2003). However, oligosaccharides are minor
IgE epitopes (Bublin et al., 2003; Okano et al., 2004) and the clinical significance of
carbohydrate determinants is controversial (Fotisch et al., 2001).
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2.3.3 Enzyme activity
Extracellular endogenous proteases, as well as exogenous proteases from mites and molds,
react with cell-surface receptors in the airways to generate leukocyte infiltration and to
amplify the immune responses to allergens (Reed et al., 2004). For example, the mite
allergens Der p 1, Der p 3, Der p 6 and Der p 9 are proteases (Chapman et al., 2007).
Protease-activated receptors (PARs) are widely distributed on the cells of the airway, where
they contribute to inflammation, an important characteristic of allergic diseases (Reed et al.,
2004). PAR stimulation of epithelial cells opens tight junctions, causes desquamation, and
induces the production of cytokines, chemokines, and growth factors. Proteases of mites and
molds appear to act through similar receptors. They amplify IgE production to allergens,
degranulate eosinophils, and generate inflammation, even in the absence of IgE
(Asokananthan et al., 2002; Miike et al., 2003). Kheradmend et al. has found that fungal
protease allergens delivered to the airways elicited a direct Th2-type immune response
(Kheradmand et al., 2002). It has been suggested that proteases from mites and fungi growing
in damp, water-damaged buildings might form the basis for the increased prevalence of
symptoms of rhinitis, asthma, and other respiratory diseases among individuals residing in
these buildings.
2.3.4 Lipocalin allergens
Lipocalins comprise a large group of proteins that are found in vertebrates, invertebrates,
plants and bacteria (Åkerström et al., 2000; Bishop, 2000; Hieber et al., 2000). The lipocalin
family is divided into two subgroups, based on the presence of the conserved sequence motifs.
The kernel lipocalins have three and outlier lipocalins one or two of these motifs (Flower et
al., 2000). The sequence similarity is low, typically below 35% (Akerstrom et al., 2000). On
the other hand, high sequence similarities also exist. For example, human tear lipocalin (TL)
and dog Can f 1 have 61% sequence identity (the SIB BLAST network service at the Swiss
Institute of Bioinformatics, April 5, 2007) and the sequence identity between horse Equ c 1
and cat Fel d 4 is 67% (Smith et al., 2004) (the SIB BLAST network service at the Swiss
Institute of Bioinformatics, April 5, 2007). Despite the low similarity in their sequences,
lipocalins share a similar three-dimensional (3D) structure; for example, the structures of TL
and cow Bos d 2 are very close, even though their sequence identity is only 18% (Rouvinen et
al., 1999; Breustedt et al., 2005). Studies using X-ray crystallography have shown the
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lipocalin structure to consist of an eight-stranded antiparallel b-barrel that forms a ligand-
binding pocket and one a-helix (Flower et al., 2000).
 Lipocalins have several different functions. They can act as transporter proteins of small,
principally hydrophobic molecules, such as retinoids, steroids, odorants and pheromones
(Flower, 1996; Åkerström et al., 2000). Moreover, they can function as modulators of cell
growth and metabolism or regulators of immune response (Åkerström et al., 2000; Lögdberg
et al., 2000). Since lipocalins are proteins that are present both in animals and humans it has
been hypothetized that the allergenicity of lipocalins is caused by misrecognition between
endogenous lipocalins and exogenous lipocalin allergens (Virtanen et al., 1999).
 Most of the major as well as minor mammalian respiratory allergens included in the
Official Nomenclature of the International Union of Immunological Societies (IUIS) are
lipocalins (Table 1). The major allergen of cat, Fel d 1, is a unique allergen among other
animal-derived respiratory allergens since it is not a lipocalin (Kaiser et al., 2003). However,
the recently identified cat allergen, Fel d 4, belongs to the lipocalins (Smith et al., 2004).
Furthermore, a food allergen beta-lactoglobulin found in cow's milk (Bos d 5) is also
lipocalin. Other lipocalin allergens are from invertebrates, Bla g 4 from the cockroach, Tria p
1 from the California kissing bug (Virtanen et al., 2004), and Arg r 1 from the pigeon tick
(Hilger et al., 2005).
 Lipocalin allergens are found in both monomeric and dimeric forms (Virtanen et al., 2004).
Half of the inhalant lipocalin allergens are glycosylated or have a putative glycosylation site.
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Table 1. Mammalian respiratory lipocalin allergens
1) only the N-terminus is known, 2) m monomer, d dimer
1.(Mäntyjärvi et al., 1996), 2.(Ylönen et al., 1992), 3.(Konieczny et al., 1997), 4. (Saarelainen
et al., 2004), 5. (Kamata et al., 2007), 6. (Fahlbusch et al., 2002) 7. (Fahlbusch et al., 2003),
8.(Gregoire et al., 1996),  9.(Lascombe et al., 2000), 10.(Bulone et al., 1998), 11.(Dandeu et
al., 1993), 12. (Smith et al., 2004), 13. (Price et al., 1987), 14. (Cavaggioni et al., 2000), 15.
(Saarelainen et al. 2007), 16.  (Baker et al., 2001), 17. (Heederik et al., 1999)
2.3.5 Recombinant allergens
Since the use of natural allergen extracts poses several problems not existing with
recombinant proteins, the recombinant allergens could provide essential tools for the
diagnostics and immunotherapy of allergy, as well as for investigating the cellular
mechanisms of immediate hypersensitivity and the molecular basis of inflammatory reactions
(Chapman et al., 2000). The key advantage of recombinant allergens compared with allergen
extracts is standardization. Even in so-called standardized preparations, allergen composition
and content can vary. Moreover, irrelevant proteins can even cause new sensitizations
(Moverare et al., 2002a). Natural products are also at high risk of being contaminated with
Animal IgE
prevalence (%)
Glycosylation Oligomeric
state 2)
Ref
Cow Bos d 2 >90 no m 1-2
Dog Can f 1 50-75 putative m+d 3-5
Can f 2 25-28 yes m+d 3-5
Can f 4 1) 60 - - 3
Guinea pig Cav p 1 1) 70 no m+d 6
Cav p 2 1) 55 no - 6-7
Horse Equ c 1 80 yes d 8 -9
Equ c 2 1) 50 no - 10-11
Cat Fel d 4 63 putative m 12
Mouse Mus m 1 50-66 no m 13-15
Rabbit Ory c 1 1) - yes - 16
Ory c 2 1) - - - 16
Rat Rat n 1 9.7 yes m 14. 17
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allergens from other sources and thus containing proteolytic enzymes. The enzymes could be
allergenic or nonallergenic, but in either case, they can lead to degradation and loss of potency
when administered together with other allergens during immunotherapy. Furthermore, most
food allergens can easily be degraded by physical and/or chemical strain during the extraction
prosess (Bohle et al., 2004).
 Another advantage of recombinant allergens is that they can be produced in large
milligram or gram quantities with high purity. Additionally, they can be easily standardized in
mass units (Bohle et al., 2004). Recombinant allergens are produced in bacterial, yeast, or
insect cells without biological or batch-to-batch variation in the product (Chapman et al.,
2000; Slater, 2004). In contrast, the final amount of an allergen in an extract depends on the
raw material used and the methodology applied to extract the protein.
 Recombinant allergen-based diagnostic tests have been shown to improve sensitivity
compared to extract-based tests (Ballmer-Weber et al., 2002; Bohle et al., 2004; van Hage-
Hamsten et al., 2004). For example, the sensitivity of SPTs for diagnosing cherry allergy has
been shown to be higher with a panel of recombinant cherry allergens than with the
commercially available cherry extract (Ballmer-Weber et al., 2002). In the study of Ballmer-
Weber et al., all the patients had a positive result to cherry in a double-blind placebo-
controlled food challenge (DBPCFC). Futhermore, 96% of the patients had a positive SPT
result with the panel of recombinant proteins, whereas the cherry extract produced a positive
SPT result in only 20% of the patients (Ballmer-Weber et al., 2002).
 Moreover, recombinant allergens would make it possible to precisely identify patients’ IgE
reactivity profile. Therefore, an optimal combination of the allergens can be selected for
immunotherapy (van Hage-Hamsten et al., 2004). When recombinant allergens are used in
microarray testing of allergen-specific IgE, a larger amount of information can be achieved
with a smaller amount of serum (Jahn-Schmid et al., 2003).
 A problem in using recombinant proteins produced in E.coli would be the improper folding
or lack of posttranslational modifications of the allergen. For example,  Lol p 1 and Lol p 5
produced by E.coli have been shown to have lower binding capacity than their natural
counterparts, thus giving rise in false negative results in RAST (van Ree et al., 1998). These
problems, however, can be solved by using eukaryotic expression systems, such as that of the
yeast Pichia pastoris, which enables posttranslational modifications. It is for this reason that
Pichia pastoris has today become the major system for expressing recombinant allergens
(Macauley-Patrick et al., 2005).
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2.4 Cross-reactivity
2.4.1 Antibody cross-reactivity
2.4.1.1 General
Antibody cross-reactivity is the ability of an antibody to bind to an antigen (or allergen) that is
different from the one that has induced its synthesis. Two types of antibody cross-reactivity
occur: symmetric and asymmetric (Aalberse, 2007). When the multivalent allergens share
epitopes, the allergens can inhibit each others' specific IgE binding in a similar manner and
the cross-reactivity is symmetric (Weber, 2001). Typical examples include plant profilins
(Radauer et al., 2006b). However, the usual finding with the birch allergen Bet v 1 is that the
allergen inhibits IgE binding to an apple allergen in a similar or even better way than the
apple allergen (Vanek-Krebitz et al., 1995; Kinaciyan et al., 2007). The apple allergen only
partially inhibits IgE binding to Bet v 1. In this case, the cross-reactivity is asymmetric, and
the epitopes are partly the same (Weber, 2001). The cross-allergenicity seems to reflect the
taxonomy in the great majority of cases with pollen allergens (Weber, 2003). IgE cross-
reactivity has also been observed among allergens of taxonomically related animals
(Savolainen et al., 1997).
 Cross-reactivity has been considered to result from the high sequence similarity. Pan-
allergens, such as lipid transfer proteins (about 95%) and polcalcins (64%-92%), share a high
degree of sequence identity (Sankian et al., 2005; Radauer et al., 2006a) and are thus highly
IgE cross-reactive (Radauer et al., 2006a). However, it seems that a high structural homology
of pan-allergens plays an important role in IgE-mediated poly-sensitization (Fluckiger et al.,
2002). This is reasonable, since IgE-epitopes are known to be conformational (Limacher et al.
2007). The view that similarity at the three dimensional (3-D) level may be more important
than similarity at the sequence level is also supported by recent studies of profilins (Sankian
et al., 2005), the Bet v 1 family, and an nsLTP subfamily of prolamin (Jenkins et al., 2005).
However, high structural similarity does not always result in cross-reactivity (Aalberse,
2000). Furthermore, the sequence identity of at least 50% of most pollen allergens seems to
be prerequisite for allergenic cross-reactivity (Radauer et al., 2006a).
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2.4.1.2 Plant and food allergens
IgE cross-reactivity among allergens is common and has widely been studied, especially in
pollen and food allergies (Radauer et al., 2006a). Among those patients with allergies to birch
pollen who suffer from such clinical syndromes as hay fever and asthma, up to 80% also
show hypersensitivity to fresh fruits and vegetables (Neudecker et al., 2001; Ferreira et al.,
2004). In the pollen–food allergy syndrome, the pollens and foods are not usually botanically
related but nonetheless do contain conserved homologous proteins, such as profilins.
Although only 10% to 20% of the patients with pollen allergies are sensitized to profilins
(Wensing et al., 2002), they are responsible for cross-reactivity, for example, among mugwort
pollen-celery-spices and among grass pollen-celery-carrots (Ferreira et al., 2004; Weber,
2001). Approximately 30 to 50% of latex-allergic persons are also allergic to specific plant
foods (Wagner et al., 2004). Class I chitinases containing a small N-terminal hevein domain
are described as the most important pan-allergens associated with a latex-fruit syndrome
(Diaz-Perales et al., 2002; Karisola et al., 2005). Moreover, consistent with the pollen-food
syndrome, the IgE cross-reactivity of profilins has been shown to be one cause for latex-fruit
syndrome, as well (Wagner et al., 2004).
 It seems that in pollen-food and latex-fruit syndromes, the patients are primarily sensitized
to pollen or latex allergens and subsequently react to food allergens. This is also supported by
the finding that the IgE from patients with latex allergy bound with much higher efficiency to
hevein and prohevein than to proteins from fruit (Karisola et al., 2005). Moreover, allergy to
fresh fruits and vegetables is much more common among patients with pollinosis than among
those without pollen allergy (Egger et al., 2006).
 The inhibitory capacity of the cross-reactive plant and food allergens can be very strong.
For example, a study of peanut allergen rAra h 8 and Bet v 1 showed that they similarly
inhibited (80-100%) IgE binding to a peanut allergen extract (Mittag et al., 2004). In the study
of Radauer et al., in which Phl p 12-specific IgE binding was inhibited with several profilins,
most of the inhibitions were over 70%, and half of the inhibitions were over 90% (Radauer et
al., 2006b).
2.4.1.3 Animal allergens
Even though IgE cross-reactivity among plant, food and arthropod allergens has received
much attention, cross-reactivity among mammalian animal allergens remains poorly
39
understood. Only a few studies have focused on animal allergen extracts, e.g., dog, cat and
cow extract, (Spitzauer et al., 1995; Savolainen et al., 1997; Cabanas et al., 2000; Ferrer et al.,
2006; Reininger et al., 2007) and purified allergens (Fahlbusch et al., 2003; Kamata et al.,
2007) .
 Since animal serum albumins have a highly conserved sequence similarity and 3-D
structure, it is not surprising that they have been studied most often. According to the Swiss-
Prot protein database, the sequence identities among albumins range from 75% to 83%. Dog
and cat albumins have been demonstrated to be IgE-cross-reactive (Spitzauer et al., 1995;
Cabanas et al., 2000; Pandjaitan et al., 2000). Cabanas et al. reported that dog albumin
inhibited IgE binding to cat albumin at a high percentage (71-100%). However, inhibition of
the binding of dog albumin-specific IgE with cat albumin was lower (49-99%)(Cabanas et al.,
2000). Therefore, it was thought that cat and dog albumins share some common (Spitzauer et
al., 1995), though protein-specific determinants (Cabanas et al., 2000). Furthermore, dog
albumin has been shown to have IgE cross-reactivity with the albumins of mouse, chicken, rat
(Spitzauer et al., 1994), guinea pig (Spitzauer et al., 1995), horse (Cabanas et al., 2000) and
man (Pandjaitan et al., 2000).
 In addition to albumins, the IgE cross-reactivity has been described for a few purified
mammalian respiratory allergens. Characterization of the major lipocalin allergens of guinea
pig revealed that Cav p 1 and Cav p 2 have IgE-cross-reactive epitopes (Fahlbusch et al.,
2003). Moreover, Cav p 1 showed IgE cross-reactivity with a guinea pig allergen with a
molecular mass of 14 kDa (Fahlbusch et al., 2003). Lipocalin allergens of dog, Can f 1 and
Can f 2, have also been shown to be IgE-cross-reactive (Kamata et al., 2007). It was recently
observed that IgE binding to the cat lipocalin allergen Fel d 4 can be blocked by an allergen
extract from cow and to a lesser degree by extracts from horse and dog (Smith et al., 2004).
Recently, the major cat allergen Fel d 1 has been shown to be IgE-cross-reactive with an
allergen in dog dander (Reininger et al., 2007).
2.4.1.4 Exogenous allergens and their endogenous human homologs
Interestingly, several allergens have been shown to IgE cross-react with their human
counterparts. Valenta et al. reported for the first time in 1991 about the cross-reactivity
between plant profilins and human profilin (Valenta et al., 1991). Thereafter, human serum
albumin (Pandjaitan et al., 2000), human acidic ribosomal P2 protein (Mayer et al., 1999),
human cyclophilins CyP A and CyP B (Fluckiger et al., 2002), and calcium-binding protein
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Hom s 4 (Aichberger et al., 2005) have been shown to be IgE cross-reactive with exogenous
allergens. It has been suggested that molecular mimicry leading to cross-reactivity between
environmental allergens and their human counterparts is due to the primary sensitization to
environmental allergens (Budde et al., 2002; Aichberger et al., 2005; Limacher et al., 2007).
Furthermore, a study with human manganese superoxide dismutase (MnSOD) and MnSOD of
Aspergillus fumigatus and Malassezia sympodialis confirmed recently that IgE-mediated
autoreactivity against a human protein is one mechanism involved in the exacerbation of AD
(Schmid-Grendelmeier et al., 2005).
2.4.2 T-cell cross-reactivity
2.4.2.1 Antigen recognition by T cells
It has been known for almost ten years that a T cell can recognize more than one ligand
(Wucherpfennig, et al., 1995; Hemmer et al., 1997). The peptides that associate with MHC
Class II are 12-20 amino acids in length (Godkin et al., 2001). The peptide has several amino
acid positions that are more occupied than others for the binding into MCH and TCR. The
positions 1, 4, 6 and 9 of the minimal peptide epitope are the anchor amino acids for MHC II
while the residues in positions 2, 3, 5, 7, and 8 are available to interact with the TCR
(Sant'Angelo et al. 2002). Moreover, the MHC II anchor residues are often hydrophobic in the
peptide (Yassai et al., 2002). Initial studies demonstrated that one or a few amino acids of a
peptide in MHC anchor positions could be replaced without loss of T-cell recognition as long
as peptide binding to the MHC is maintained (Stern et al., 1994). Subsequently, this concept
was refined so that no single residue was strictly required for recognition as long as the
available residues provided enough binding energy for MHC and TCR (Hemmer et al., 1998).
Hemmer et al. further demonstrated that antigen recognition by CD4+ T cells is defined by
several different factors. One of them is the baseline affinity of the TCR for the MHC
(Hemmer et al., 2000). Moreover, the antigenic recognition by T cells is also influenced by
the individual contribution of each amino acid residue but also by the synergistic effects of
certain amino acid combinations of the antigenic peptide (Hemmer et al., 2000). Recently,
Sant'Angelo et al. have shown that no specific interactions occurred between peptide flanking
residues and TCR (Sant'Angelo et al. 2002). However, the peptide flanking residues
contribute substantially to MHC binding  (Sant'Angelo et al. 2002).
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 Wucherphennig et al. hypothesized that TCR recognition is characterized by a considerable
degree of cross-reactivity and that a TCR could recognize a number of different peptides that
might be rather distinctive in their sequence (Wucherpfennig, 2004). This flexibility in T cell
recognition is proposed to be caused by several factors (Holler et al. 2004), such as
conformational chances of a single TCR (Reiser et al. 2003). Based on observations with a
subset of T-cell clones that can be activated by combinatorial peptide libraries, it has been
postulated that a single TCR can recognize 106 different peptide ligands (Mason, 1998). Thus,
T-cell cross-reactivity may be much more difficult to predict than B-cell cross-reactivity, in
which the sequence homology should typically be over 50% (Radauer et al., 2006a). Although
a T cell can recognize a large repertoire of ligands, most of the peptides are recognized with
low-affinity interaction (Zhou et al., 2004). Furthermore, despite the fact that longer peptides
are involved in the Th-cell-MHC class II interaction compared to the cytotoxic T-cell-MHC
class I interaction, the specificity of the former interaction is even lower than that of the latter
(Aalberse, 2005). TCR cross-reactivity appears to be a general property of T-cell recognition
as well as a critical aspect of T-cell development in the thymus (Wucherpfennig, 2004).
2.4.2.2 Exogenous allergens and their endogenous human homologs
T-cell cross-reactivity, e.g., between pollen and related food allergens occurs independently of
IgE cross-reactivity (Bohle, 2007). The major birch allergen Bet v 1 has T-cell cross-reactive
epitopes, for example, with Api g 1, the major allergen in celery (Bohle et al., 2003), as well
as Cor a 1 and Dau c 1, the major allergens in hazelnut and carrot, respectively (Jahn-Schmid
et al., 2005). The proliferative and cytokine response to the group 1 and 7 allergens of
Dermatophagoides pteronyssinus and D. farinae indicates a large degree of T-cell cross-
reactivity between the purified allergens from each species (Hales et al., 2000). Moreover,
human T-cell cross-reactive epitopes have been demonstrated, for example, between the
Japanese cypress pollen allergen Cha o 1 and the Japanese cedar allergen, Cry j 1 (Sone et al.,
2005) and between the profilin allergens Bet v 2 and Phl p 12 (Burastero et al., 2004). The
results suggest that a modulation of the response to one sensitizing allergen can occur
following natural exposure or following  immunotherapy with another allergen (Burastero et
al., 2004).
 Molecular mimicry is characterized by an immune response to an environmental agent that
cross-reacts with a host antigen, resulting in a disease. Molecular mimicry, also called
epitopic and antigenic mimicry, is one of the leading theories that attempts to explain why the
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immune system turns against its own body in autoimmune diseases, such as multiple
sclerosis, rheumatoid arthritis, and type 1 diabetes. For example, the autoantigen of the
pancreatic beta cell GAD65 has been shown to cross-react with cytomegalo viruses (Roep et
al., 2002). Furthermore, T cells or T-cell clones from multiple sclerosis (MS) patients have
been shown to cross-react with virus peptides, such as peptides of an influenza virus
(Markovic-Plese et al., 2005). Zhou and Hemmer have discussed that the probability of
autoimmunity increases with the increasing affinity of TCRs for the cross-reactive antigen.
Therefore, cross-reactivity that leads to autoimmunity is more likely to occur if the affinity of
the mimicking peptide approaches the affinity of the initial microbial antigen (Zhou et al.,
2004). This hypothesis is supported by the results of several studies (Hennecke et al., 2001;
Zhou et al., 2004).
 It has also been suggested that an environmental allergen mimicking the self may represent
an important pathomechanism involved in the maintenance and exacerbation of severe and
chronic forms of allergy (Bünder et al., 2004). In atopic dermatitis, T-cell mediated
autoimmunity against manganese superoxide dismutase (MnSOD) may be due to primary
sensitization through fungal MnSOD (Schmid-Grendelmeier et al., 2005). Moreover, it has
been discussed that the chronic manifestations of atopic diseases, such as chronic skin lesions
of atopic eczema, are accompanied by a mixture of Th1 and Th2 cytokine production (Hamid
et al., 1994; Truyen et al., 2006; Wang et al., 2007). This is in line with the study of Bünder et
al. showing that sensitization with a foreign antigen mimicking self can induce an allergic
immune response of a mixed Th2 and Th1 cytokine profile (Bünder et al., 2004).
2.4.3 Significance of the IgE and T-cell cross-reactivity
2.4.3.1 Clinical significance
 Demonstration of IgE cross-reactivity in vitro is not always reflected in cross-reactivity in
vivo (Aalberse et al., 2001). For example, IgE cross-reactivity of cross-reactive carbohydrate
determinants (CCD) seems to have limited clinical relevance (Wensing et al., 2002). Kochuyt
et al. have shown that patients allergic to hymenoptera stings have specific IgE to venom
glycoproteins which cross-reacts with CCD in pollen. This IgE cross-reactivity of CCD may
cause false positive IgE antibody results with pollen allergens in up to 16% of hymenoptera-
allergic patients, thus leading to the possibility of a misdiagnosis of multivalent pollen
sensitization (Kochuyt et al., 2005). Moreover, Wensing et al. have suggested that
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monosensitization to profilins can also be accompanied by several positive RAST results
without any clinical relevance (Wensing et al., 2002).
 IgE cross-reactivity may be exploited in allergy diagnostics. For example, the grass-pollen
allergen rPhl p7 which belongs to calcium-binding (EF-hand) pollen allergens, contains the
most IgE epitopes present in allergens of other calcium-binding allergen families (Tinghino et
al., 2002). Therefore, it could serve as a useful diagnostic marker to identify patients who
have become sensitized to several IgE-cross-reactive EF-hand allergens (Tinghino et al.,
2002). Furthermore, Niederberger and co-workers have shown that the recombinant pollen
allergens Bet v 1 and Bet v 2 contain most of the IgE epitopes present in birch and other
members of the Fagales family (Niederberger et al., 1998). Consequently, it may be possible
to use these allergens as representative molecules for the diagnostics and therapy of birch-
related pollen and food allergies (Niederberger et al., 1998).
 In some situations, such as with major allergens of botanically-related grasses, it is
impossible to determine the sensitizing allergen without information on allergen exposure
(Aalberse, 2007). Highly IgE-cross-reactive allergens, such as profilins (Wopfner et al., 2002;
Radauer et al., 2006b), can elicit clinical symptoms in patients sensitized to one of them
(Wensing et al., 2002; Radauer et al., 2006b). Moreover, pollen-associated food allergy is
usually caused by IgE-cross-reactivity between birch pollen allergen Bet v 1 and certain food
allergens (Bohle, 2007). For example, Bet v 1 was found to initiate sensitization to the major
allergen in celery, Api g 1 (Bohle et al., 2003). In addition to IgE cross-reactivity, T-cell
cross-reactivity may have clinical implications. The activation of Bet v 1-specific Th2 cells by
related food allergens, in particular outside the pollen season, may cause ‘visible’ clinical
symptoms, e.g., deterioration of atopic eczema, without immediate clinical symptoms of food
allergy (Bohle, 2007). Ingestion of birch-pollen related food could also maintain perennially
increased allergen-specific IgE levels (Bohle et al., 2003; Bohle, 2007). This view is
supported by the study of Burastero et al. whose study showed that a significant proportion of
IgE cross-reactivity can result from the T-cell help to B cells provided by Th2 cells which are
activated by pan allergens (Burastero et al., 2004).
2.4.3.2 Immunological significance
Discussion on the significance of T-cell cross-reactivities between self antigens and microbial
antigens has been controversial. Although the role of cross-reactivity in initiation of the
autoimmune diseases or allergy is uncertain, it may be important in regulating and
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exacerbating the disease. This view is in line with the finding that autoreactive T cells are not
confined to MS patients but are also found in healthy donors (Tejada-Simon et al., 2001). The
result further suggests that autoreactive T cells are part of the normal T-cell repertoire and not
necessarily harmful (Tejada-Simon et al., 2001).
 The high affinity IgE receptor, FceRI, has a central role in the initiation and control of
atopic allergic inflammation (von Bubnoff et al., 2003). It is expressed on the surface of
effector cells, such as mast cells and basofils (Kay, 2001), but more importantly, it is also
expressed on the surface of antigen-presenting cells, such as dendritic cells from atopic
(Allam et al., 2003; Foster et al., 2003) and nonatopic patients (Allam et al., 2003). It has been
speculated that IgE-cross-reactive proteins, especially endogenous proteins that are IgE-cross-
reactive with exogenous allergens, could regulate or tolerize an allergic immune response
(Aalberse et al., 2001), e.g., through this receptor (von Bubnoff et al., 2003).
 After FceRI cross-linking, the production of tryptophan-catabolizing enzyme indoleamine
2,3-dioxygenase (IDO) might comprise part of a mechanism to suppress unwanted T-cell
responses (von Bubnoff et al., 2003). Tryptophan is critical to the generation of T-cell
responses (Gordon et al., 2005). Furthermore, IDO-driven tryptophan consumption by APCs
can lead to deletion of the contacting T cells through the induction of apoptosis (von Bubnoff
et al., 2002; Gordon et al., 2005). Since IDO is a rate-limiting enzyme, T-cell suppression can
be prevented by addition of tryptophan or by inhibition of IDO (von Bubnoff et al., 2002).
Several reports have shown that monocytes and dendritic cells can inhibit T-cell proliferation
(Grohmann et al., 2001; Mellor et al., 2004) and tolerize Th2 responses both in vitro and in
vivo through IDO (von Bubnoff et al., 2003; Gordon et al., 2005). Recently, it has been
suggested that in addition to DCs, eosinophils may also express IDO (Odemuyiwa et al.,
2004).
45
3. AIMS OF THE STUDY
As the knowledge of the immunological characteristics of animal-derived lipocalin allergens
is limited the purpose of the study was to clarify the lipocalin allergen-specific immune
responses of mice and humans. Furthermore, since the recombinant allergens provide an
essential tool for the research and diagnostics of allergy the suitability of recombinant dog
allergens for dog allergy diagnostics was assessed.
The aims of the study were
1. To analyze immune response to Bos d 2 and to its immunodominant epitope p127-142 in a
mouse model (I-II).
2. To examine T-cell and IgE-cross-reactivities among lipocalin allergens and endogenous
lipocalins (II, IV).
3. To elucidate the suitability of recombinant dog allergens Can f 1 and Can f 2 for the
diagnostics of dog allergy (III).
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4. MATERIALS AND METHODS
4.1 Immunization of mice (I-II)
For study I, six- to eight-week-old female mice (A.SW (H-2s), A/J (H-2s), BALB/c (H-2d),
B10.M (H-2f), C57BL/6 (H-2b), CBA (H-2k)) were obtained from The National Laboratory
Animal Center (Kuopio, Finland). For study II, mice (BALB/c (H-2d), C57BL/6 (H-2b), CBA
(H-2k)) of the same age were obtained from Taconic M&B A/S (Ry, Denmark). The mice
were maintained under pathogen-free conditions throughout the study. In study I, the mice
were injected at two-week intervals intraperitoneally (i.p.) or subcutaneously (s.c.) at the base
of the tail, up to four times with antigens (25µg-500µg). Alum (prepared as described in
manuscript I), Imject Alum (Pierce, Rockford, USA), incomplete Freund's adjuvant (IFA;
Sigma; F5506) or complete Freund's adjuvant (CFA; Sigma; F5881) were used as adjuvants.
In study II, the mice were injected s.c. at the base of the tail with peptides (0.005µmol) in
complete Freund's adjuvant. The control mice were treated with phosphate-buffered saline
(PBS), CFA or tetanus toxoid in CFA. The blood, spleen and inguinal lymph node samples
were collected 10 days after the last immunization. Experiments were performed with the
permission of the European Convention for the Protection of Vertebrate Animals used for
Experimental and Other Scientific Purposes (Strasbourg 18 March 1986, adopted in Finland
31 May 1990). The study was approved by the Animal Care and Use Committee of the
University of Kuopio.
4.2 Subjects (III-IV)
Subjects with dog (III-IV), cow, horse or mouse allergy (IV) diagnosed at the Department of
Pulmonary Diseases of Kuopio University Hospital, subjects with self-reported symptoms of
mouse allergy (IV), healthy nonatopic subjects (IV) and healthy nonatopic dog owners (III-
IV) were recruited for the studies (Table 2). Partly the same subjects participated in studies
III-IV. A subject was classified as allergic if the result of UniCAP fluoroenzyme-
immunometric assay (FEIA) (Pharmacia, Uppsala, Sweden) was >0.7kU/l or the result of
skin prick test (SPT; epithelial preparations from ALK Abelló, Hørsholm, Denmark) was ?3
mm with the allergen extract. SPTs were performed according to European recommendations
(Dreborg 1993) in duplicates on the backs of the allergic and/or control subjects. In SPT the
rCan f 1, rCan f 2 (III), rEqu c 1 and rMus m 1 were used at ten-fold dilutions from 250µg/ml
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to 0.025µg/ml (IV). The dilutions were made in 0.9% NaCl immediately before the test.
Histamine hydrochloride (10 mg/ml) and diluent (0.9% NaCl) were included as positive and
negative controls, respectively. After 15 min, the wheals were marked and documented by
direct tracing onto strips of tape. The means of the longest and the midpoint orthogonal
diameters of the duplicates were calculated and the mean values of ³ 3mm were considered
positive. The total serum IgE of dog-allergic and healthy dog owners was measured by
immuno-enzymometric assay (IEMA) using chemiluminescence substrate (Diagnostic
Products Corporation, Los Angeles, CA, USA) (III). The studies were approved by the Ethics
Committee of the Kuopio University Hospital.
Table 2. The subject in  studies III-IV
Study Subjects SexFemale /Male Age (years)±SD
III Dog-allergic patients
n=25 13 / 12 39±9
Healthy nonatopic dog owners
n=11 8 / 3 43±13
IV Dog-allergic patients
n=31 15 / 16 41±9
Cow-allergic patients
n=18 8 / 10 39±9
Horse-allergic patients
n=21 12 / 9 43±11
Mouse-allergic patients
n=15 6 / 9 36±10
Healthy nonatopic subjects
n=21 14 / 7 38±13
4.3 Allergen preparations
4.3.1 Cloning and production of recombinant proteins in Pichia pastoris yeast (I, III- IV)
The expression of recombinant Can f 1, Can f 2, (III-IV), Bos d 2 (I, IV), Equ c 1 (IV), Mus
m 1 (IV) and human tear lipocalin (TL) (IV), was done in P. pastoris (Invitrogen, CA, USA).
For rCan f 1, total RNA was isolated from the tongue tissue, for rCan f 2 from the parotid
gland of a male dog, and for Equ c 1 from the sublingual tissue of horse. The isolation was
made with the RNAgents® total RNA isolation system (Promega, Madison, WI, USA)
following the manufacturer's instructions. First-strand cDNAs were synthesized using random
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hexanukleotides. A plasmid containing TL cDNA (a kind gift from Dr. Bernhard Redl,
Institut für Molekularbiologie, Innsbruck, Austria) was used as a template for generating the
rTL construct.
 To generate the DNA constructs encoding Can f 1, Can f 2, Equ c 1, and TL, specific
primers were designed based on the published nucleotide sequences of the proteins (Gregoire
et al., 1996; Holzfeind et al., 1996; Konieczny et al., 1997). For the 3´ primers, polyhistidine
tag sequences were included. The amplifical products were subcloned into the pPIC9
(Invitrogen, CA, USA) (Can f 1, Equ c 1, and TL) and pHILS1 (Invitrogen, CA, USA) (Can f
2) expression vectors. All generated vector constructions were verified by DNA sequencing
using Thermo Sequence CY5 Dye Terminator Kit and A.L.F Express DNA Sequencer
(Amersham Pharmacia Biotech, Uppsala, Sweden). P. pastoris was transformed with the
vector constructs, and the proteins were produced following the manufacturer’s instructions
(Invitrogen, CA, USA).
The P. pastoris expression clone pHIL-D2MUP for rMus m1 was a kind gift from Dr.
Elena Ferrari, Istituto di Chimica Biologica, Facolta di Medicina e Chirurgia, Universita di
Parma, Italy. Recombinant Bos d 2 was constructed as previously reported (Rautiainen et al.,
1998; Rouvinen et al., 1999).
 Histidine-tagged recombinant proteins (Can f 1, Can f 2, Equ c 1 and TL) were purified
with the HisTrap Kit (Amersham Pharmacia Biotech AB, Uppsala, Sweden) according to the
manufacturer's instructions. The rMus m 1 was purified using Äktapurifyer (Amersham
Pharmacia Biotech AB, Uppsala, Sweden) with the Resource Q column (Amersham
Pharmacia Biotech AB, Uppsala, Sweden) and NaCl gradient in Tris-HCl buffer, basically as
described by Ferrari et al. (Ferrari et al., 1997). The subsequent gel filtration to recombinant
proteins was performed with Superdex 75 media (Amersham Pharmacia AB, Uppsala,
Sweden) with Natrosteril 0.9 (Orion OY, Espoo, Finland) or PBS as an eluent. Recombinant
psoriasin which was used as a control protein in immunoblot inhibition assays was produced
and purified, as described previously (Porre et al., 2005).
 The purities of the preparations were verified by SDS-PAGE and IgE immunoblotting with
monoclonal Anti-His6 (Roche, Mannheim, Germany) (Can f 1, Can f 2, Equ c 1, TL), rabbit
immune sera (Mus m 1 and TL) or patient sera (Can f 1, Can f 2, Equ c 1, Bos d 2).
Recombinant Equ c 1 was expressed as a dimer. rTL was expressed in both dimeric and
monomeric forms, and the rest of the proteins in monomeric forms. The recombinant proteins
were subjected to in-gel digestion, as described previously (Rautiainen et al., 1995), with
slight modifications. The sequences of the tryptic digests of the proteins were analyzed by
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HPLC-electronspray ionization mass spectrometry, as described previously (Rautiainen et al.,
1998). Protein concentrations were determined by the method of Bradford using the BioRad
(Hercules, CA, USA) protein assay or by absorbance spectroscopy using the molar absorption
coefficient (Curr. prot. in protein science). Sterile-filtered preparations were stored at -70?C.
4.3.2 Synthetic peptides (I-II)
For the epitope mapping of Bos d 2 (I), the 16-mer peptides overlapping by 14 amino acid
residues and covering the Bos d 2 sequence were synthesized using a simultaneous multiple-
peptide synthesizer (SMPS 350, Zinsser Analytic, Frankfurt, Germany) by Fmoc (N-[9-
fluorenyl]methoxycarbonyl) chemistry, as reported previously (Kinnunen et al., 2003). The
peptides were desalted and purified by reverse phase high–pressure liquid chromatography
(HPLC).
 The Bos d 2 peptide p127-142 (ELEKYQQLNSERGVPN) (I), its 16-mer analogs,
truncated derivatives, and other peptides (II) were synthetisized using PerSeptive 9050 Plus
automated peptide synthesizer (Millipore, Bedford, MA) with Fmoc strategy. The peptides
were purified by HPLC (Shimadzu, Tokio, Japan) with a C18 reverse phase column and
acetonirile as eluent (0.1% TFA in H20/0-60% acetonirile gradient for 60 min). All the
peptides (I-II) were verified with the MALDI-TOF mass spectrometer (Bruker, Bremen,
Germany). No signs of impurities, e.g., endotoxin, were observed in the analyses. The
sequences (Table 3) for the peptides SP1-SP9 homologous to p127-142 were obtained from
the Swiss-Prot protein sequence database using the program FindPatterns. The sequences for
the peptides SP10-SP20 corresponding to p127-142 were obtained by the sequence homology
alignments with lipocalin proteins (from dog, horse, cow, cockroach, mouse, rat and human)
from the same database using the program BestFit, as described previously (Kinnunen et al.,
2003). Sterile filtered or g-irradiated peptides were stored frozen at 70°C.
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Table 3. The sequences of database search peptides
4.3.3 Other allergen preparations (I,III-IV)
Natural forms of the proteins were used in studies I (nBos d 2) and IV (nMUP). Both of the
proteins were purified as their recombinant counterparts described above. The production of
Escherichia coli-produced recombinant Bos d 2, its N- and C-terminal fragments (amino
acids 1-115 and 65-156, respectively) and the fusion part glutathione S-transferase (GST)
used in study I is described elsewhere (Mäntyjärvi et al., 1996; Zeiler et al., 1997). For
sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting
analyses, the same commercial dog (III) and horse (IV) epithelial extracts, were same as for
SPTs (AKL Abelló, Hørsholm, Denmark).
Peptide Source Sequence
127-142 Natural peptide E L E K  Y Q Q L N S E R  G V P N
SP1 KIAA1224 (Human) D L E S  Y L Q L N C E R  G T W R
SP2 RBBP-1 (Human) S N Q C  I Q Q L T S E R  F D S P
SP3 YTRE (Bacillus subtilis) V L E L  I Q Q L N R E R  G I T F
SP4 5-HT-2C (Human) P R G T  M Q A I N N E R  K A S K
SP5 Nestin (Human) V R L E  L Q Q L Q A E R  G G L L
SP6 DNAE (Chlamydia pneumoniae) G K K D  F Q Q M E Q E R  E K F C
SP7 SPV1 ORF14 (Spiroplasma citri) H V I E  V Q Q I N S E R  S W F F
SP8 NF-H (Human) Y Q E A  I Q Q L D A E L  R N T K
SP9 R51H2 (Human) T R L I  L Q Y L D S E R  R Q I L
SP10 Can f 1 (Dog) A L E D  F R E F S R A K  G L N Q
SP11 Can f 2 (Dog) D F L P  A F E S V C E D  I G L H
SP12 Equ c 1 (Horse) I K E E  F V K I V Q K R  G I V K
SP13 Bos d 5 (Cow) A L E K  F D K A L K A L  P M H I
SP14 Bla g 4 (Cockroach) Y N D K  G K A F S A P Y  S V L A
SP15 Mus m 1 (Mouse) I K E R  F A Q L C E E H  G I L R
SP16 Rat n 1 (Rat) I K E K  F A K L C E A H  G I T R
SP17 A1AG (Human) L G E F  Y E A L D C L R  I P K S
SP18 TL (Human) A L E D  F E K A A G A R  G L S T
SP19 APD (Mouse) T I T Y  L K D I L T S N  G I D I
SP20 NGAL (Mouse) L K E R  F T R F A K S L  G K L D
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4.4 Immunochemical tests
4.4.1 Western blot and Western blot inhibition analyses (III-IV)
The IgE reactivity of dog (III) and horse-allergic patients (IV), as well as control patients, to
the commercial SPT preparations was detected by SDS-PAGE immunoblotting as described
previously (Rautiainen et al., 1997; Zeiler et al., 1997) with a few modifications. The IgE
reactivity of mouse-allergic patients (IV) to purified natural and recombinant MUP was
detected in the same way. In brief, SDS-PAGE-separated proteins were transferred to
nitrocellulose membranes and blocked with 1% BSA in PBS. The membrane strips were
incubated overnight with patient and control sera (1:10), washed and then incubated with
monoclonal horseradish peroxidase-labeled mouse anti-human IgE (1:2000; Southern
Biotechnology Associates. Inc, Birmingham, AL, USA). After washing, the reactive bands
were visualized with ECL detection reagents (Amersham International, Buckinghamshire,
England) according to the manufacturer’s instructions.
 The inhibition of immunoblotting was performed essentially as described previously
(Rautiainen et al., 1997). Human sera reactive to the recombinant allergens under study,
diluted at 1:12.5 (III) or 1:15 (IV), were mixed with equal volumes of recombinant allergen
dilutions (Can f 1, Can f 2, Equ c 1, and  Mus m 1)  to obtain a final protein concentration of
100µg/ml (III) or 200 µg/ml (IV). Recombinant psoriasin was used as a control protein. After
incubation for two hours at +37°C, IgE reactivity against the epithelial dog and horse
preparations or natural MUP was visualized as described above.
4.4.2 Measurements of murine antibodies (I)
Specific murine antibody responses were measured by indirect ELISAs, as described
previously with a few modifications. For measuring the specific IgG levels, the plates were
coated with natural Bos d 2 at a concentration of 1µg/ml overnight at 4°C in the coating
buffer. After blocking, the plates were stored frozen at -70°C. Serum samples were diluted
1:250. The bound IgG was detected by goat anti-mouse IgG (Biomakor, Israel; 1:1000, 0.5 h,
room temperature (rt)), followed by biotinylated rabbit anti-goat IgG (Cappel, Turnhout,
Belgium; 1:2000, 0.5h, rt). The colour reaction was developed using ABC Elite kit (Vector,
Burlingame, CA, USA), as described previously.
 The IgG subclass levels were detected as described above with minor modifications.
ELISA plates were coated with nBos d 2, HEL or TT at a concentration of 1µg/ml (IgG1) or
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50µg/ml (IgG2a). Serum samples were 10-fold diluted 1:100-1:1000 000, IgG1 and 1:10-
1:100 000, IgG2a. The bound IgG was detected by biotinylated anti-IgG1 (1:1000) or anti-
IgG2a (1:100) antibodies (Caltag, Burlingame, Ca, USA) at 37°C for 1h. The colour reaction
was developed using ABC Elite kit (Vector, Burlingame, CA, USA), as described previously.
4.4.3 Measurements of human IgE (III-IV)
To measure the lipocalin-specific IgE levels of human serum samples (Can f 1, Can f 2 in III-
IV, Bos d 2, Equ c 1 and TL in IV), indirect ELISAs were used as described previously
(Virtanen et al., 1996; Zeiler et al., 1997) with small modifications. In brief, in study III, the
plates for IgE detection were coated with 5 µg/ml of rCan f 1 and rCan f 2. Sera were diluted
at 1:10. The bound IgE was detected by rabbit anti-human IgE (1:500; Dako A/S, Glostrup,
Denmark) combined with biotinylated goat anti-rabbit immunoglobulins (1:2000; Dako A/S,
Glostrup, Denmark). The color reaction was developed using the ABC Elite kit (Vector,
Burlingame, CA, USA), as described previously.
 In study IV, the plates for IgE measurements were coated with 5 µg/ml of rCan f 1 or rCan
f 2 and 10µg/ml of Equ c 1, Bos d 2, Mus m 1 or TL. Sera were diluted at 1:10. The bound
IgE was detected by biotinylated rabbit anti-human IgE (1:1000; Southern Biotechnology
Associates. Inc, Birmingham, AL, USA) combined with streptavidin-HRP (1: 10 000;
Amersham International, Buckinghamshire, England). The color reaction was developed by
the commercial reagent (Zymed laboratories Inc. South San Francisco,CA, USA) according to
the manufacturer’s instructions.
 In studies III and IV, the cut-off for a positive reaction was defined as the mean OD of the
control subjects + 3 SD.
4.4.4 IgE Elisa inhibition tests (IV)
The ELISA inhibition was performed essentially in the same way as the indirect ELISA
measurement of human IgE described above, except for an additional preincubation of the
serum pools with inhibitor proteins. Serum pools contained sera from 4-5 allergic patients
reactive to the recombinant proteins under study. In the preincubation, the final serum dilution
was 1:10-1:50 and the lipocalin concentration from 0.6 to 200 µg/ml.  After an incubation of
one hour at +37°C, samples were added to allergen or TL-coated plates and the bound IgE
was detected as described above.
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4.5 In vitro analysis of lymphocytes (I-II)
4.5.1 Isolation and the proliferation assays of murine lymph node and spleen cells (I-II)
The spleens or lymph nodes were removed from the mice and prepared as a single-cell
suspension. The red blood cells were removed from the spleen cell suspension by lysing cells
with 0.017 M Tris-0.75% NH4Cl. Alternatively, the spleen cells were isolated by the
Lympholyte M (Cadarlane, Hornby, Ontario, Canada) density gradient centrifugation
according to the manufacturer’s instructions. The cells were suspended in culture medium:
DMEM (BioWhittaker, Walkersville, MD, USA) supplemented with 2 mM L-glutamine
(Gibco, Grand Island, NY, USA), 50 µM 2-ME, 1 mM sodium pyruvate (BioWhittaker,
Walkersville, MD, USA), 10 mM HEPES (BioWhittaker, Walkersville, MD, USA), 100
IU/ml penicillin (Orion, Espoo, Finland), 100 µg/ml streptomycin (Sigma, St. Louis, MO,
USA), and 10% inactivated fetal calf serum (Biological Industries, Beit Haemek, Israel).
Proliferation tests were performed, as described in study I. In brief, 2x105 cells/well were
incubated in triplicate in 96-well round-bottomed microtiter plates (Corning, Acton, MA)
with proteins at 12.5-100 µg/ml or peptides at 0.15-50 µM for 3 days in a humidified 5% CO2
incubator at 37°C and then pulsed for 16 h with 0.5 µCi/well [3H] thymidine (Amersham,
Little Chalfont, UK). The radionuclide uptake was measured by scintillation counting and the
results expressed as count per minute (cpm) or as stimulation indices (SI: ratio between the
mean cpm in cultures with stimulant and the mean cpm without stimulant).
4.5.2 Determination of restriction by major histocompatibility complex (II)
CD4+ T cells were separated from spleen cell suspension by SpinSeptm Cell Enrichment
Method (StemCell Technologies, Vancouver, Canada) according to the protocol of the
manufacturer. The purity of CD4+ T cells determined by flow cytometry was >95% after two
purification cycles. The CD4+ cells (1x105 cells/well) were cultured in triplicate in 96-well
round-bottomed microtiter plates with g-irradiated (6000 rad) I-Ad- or I-Ed-transfected
fibroblasts (LA(d) and LE(d)) (Texier et al., 1999) as feeder cells (0.5 x105  or 1x105
cells/well ). The p127-142 concentration ranged from 0.5 µM to 50 µM. The response was
measured by the proliferation assay.
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4.5.3 MHC class II-peptide binding assay
The competetive MHC II-peptide binding assay was performed as previously described
(Texier et al., 1999). The purified I-Ad and I-Ed molecules were incubated with serial
dilutions of competitor peptides and the biotinylated competitor peptides MYO 106-118 and
HA 306-318 peptide, respectively. The samples were incubated for 24 or 72 h for I-Ad or I-
Ed, respectively. After neutralization, the samples were incubated for 2 h at room temperature
on plates coated with 10 µg/ml MKD6 (mAb for I-Ad) or 14.4.4S (for I-Ed). The bound
biotinylated peptide was detected using a streptavidin-alkaline-phosphatase conjugate
(Amersham, UK) and 4-methylumbelliferyl phosphate substrate (Sigma, France). Emitted
fluorescence was measured at 450 nm upon excitation at 365 nm. Maximal binding was
determined by incubating the biotinylated peptide with the MHC II molecule in the absence of
a competitor. Results were expressed as the peptide concentration which prevented binding of
50% of the labeled peptide (IC50).
4.5.4 Measurement of cytokine production by murine lymph node and spleen cells
Mouse spleen or lymph node cells (I) were stimulated with nBos d 2, HEL or TT at a
concentration of 100 µg/ml at an optimal density of 3x 106 cells/ml in 4-ml test tubes in a
volume of 1.5 ml for 48h (IL-2 and IFN-g) or 96h (IL-4 and IL-5) in a humidified 5% CO2
incubator at 37°C. Positive (Con A at 5µg/ml) and negative controls (cells with culture
medium only) were included. Stimulations of the spleen or lymph node cells from mice
immunized with a peptide were performed at two peptide concentrations, 3 and 30µg/ml. An
irrelevant peptide served as a control. After stimulation, the culture supernatants were
collected, aliquoted and stored at –70°C until examined. The IL-4, IL-5, and IFN-g levels of
the supernatants were measured by ELISA in duplicate using commercial reagents (all
reagents from PharMingen, San Diego, USA) according to the manufacturer’s instructions.
The color reactions were developed as described for antibody measurements. For measuring
IL-2, the CTLL-2 cell line was used as previously described with minor modifications. The
mAb against murine IL-4 (R&D Systems, Abingdon, UK) at a neutralizing concentration
(1µg/ml) was included in the assay. A semiquantitative estimate of IL-2 production was
determined from a standard curve of rIL-2 (Strathmann Biotech, Hamburg, Germany). The
limit of detection for IL-2 was 0.05U/ml.
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4.5.5 Enumeration of cytokine-producing murine spleen cells
The ELISPOT analyses (II) of cytokine production by spleen cells were performed as
described previously (Immonen et al., 2003). Briefly, ELISPOT plates (Cellular Technology
Ltd., Reutlingen) were coated with anti-mouse IL-4 or IFN-g monoclonal antibodies
(Pharmingen, San Diego, USA) at 4 µg/ml in PBS overnight at +4°C. The medium used was
HL-1 (BioWhittaker, Walkersville, MD, USA) supplemented with 2 mM L-glutamine, 100
IU/ml penicillin and 100 µg/ml streptomycin. The spleen cells at a density of 106 cells/well
(0.2 ml) were added in duplicate in plates with peptides at concentrations ranging from 0.5 to
50 µM. The cells were incubated for 24 h (IFN-g) or 48 h (IL-4) in a humidified 5% CO2
incubator at 37°C. The produced IL-4 or IFN-g (Pharmingen) was detected by biotinylated
monoclonal antibodies (4 µg/ml) at 4°C overnight followed by streptavidin-HRP conjugate
(diluted 1:2000, Dako A/S, Denmark).  The color reaction was allowed to develop using a
solution containing 3-amino-9-ethyl carbazole (Sigma, dissolved in N-N-dimethylformamide
(Merck, Darmstadt, Germany)), 0.1 M sodium acetate, pH 5.0, and 30% H2O2 (Riedel-de
Haën, Seelze, Germany). The spots were counted under a stereomicroscope.
4.6 Statistical analyse (I, III-IV)
Statistical differences between groups were determined with the Kruskal-Wallis test and post
hoc comparisons with the Mann-Whitney U-test. For determining correlations, the Spearman
Rank Correlation test was used. Concordances for results classified as positive or negative
were determined by calculating the Phi coefficient and the Fisher’s Exact P-value (III).
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5. RESULTS
5.1 Validation of recombinant lipocalins (III-IV)
The Pichia pastoris-produced recombinant lipocalins were purified by chromatography. After
gel filtration, rCan f 1, rCan f 2 (III) and rMus m 1 (IV) were eluted as monomers. In contrast,
rEqu c 1 (IV) was eluted as a dimer and rTL (IV) at two approximate molecular sizes (20 and
40 kDa), compatible with being monomeric and dimeric forms of the protein. SDS-PAGE
revealed rCan f 1 (III), rEqu c 1, rMus m 1 and rTL (IV) as single bands with molecular
masses of  23 kDa, 26 kDa, 18 kDa, and 22 kDa, respectively, whereas rCan f 2 (III) was
revealed as two bands (23 and 25 kDa). The sequences of the tryptic digests of the
recombinant proteins obtained by HPLC-electrospray ionization mass spectrometry also
matched those reported for the proteins (Gregoire et al., 1996; Holzfeind et al., 1996; Ferrari
et al., 1997; Konieczny et al., 1997). In study III, a further mass-spectroscopic analysis of Can
f 2 showed that the higher molecular weight peptide was glycosylated with two N-acetyl
glucosamines and 8-14 hexoses, while the smaller molecular weight peptide was
unglycosylated.
 The IgE-binding capacities of natural and recombinant Can f 1, Can f 2 (III), rEqu c 1 and
rMus m 1 (IV) were verified with patient sera in immunoblotting (III, Figs. 1 and 2 and IV,
Fig. 1). The immunoblotting, skin prick test and ELISA results of studies III-IV are
summarized below in Table 4. In study III, 72% of the dog-allergic patients had IgE reactivity
against allergens in the dog epithelial SPT preparation (III, Fig.2) and 52% against Can f 1.
IgE reactivity against Can f 2 was 28%. All the patients recognizing Can f 2 also recognized
Can f 1 (III-IV). In study IV, the sera of horse- and mouse-allergic patients reactive to the
proteins corresponding to natural Equ c 1 and Mus m 1, evaluated by the molecular size (23
kDa and 20 kDa, respectively), also recognized the recombinant allergens (IV, Fig. 1).
Control sera did not show IgE binding to the recombinant allergens.
 Fig. 1 (III) and Fig. 1A (IV) show that preincubation of a single serum (III) or serum pool
(IV) with the appropriate recombinant allergens (Can f 1, Can f 2 or Equ c 1) resulted in the
elimination of IgE binding to the 22 kDa, 25 kDa or 23 kDa components in the allergen
extract, respectively. In addition, no IgE binding to the natural Mus m 1 was observed after
prior incubation with the recombinant allergen (IV, Fig. 1B).
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5.2 Antibody and skin prick test reactions to lipocalins (I, III-IV)
5.2.1 Human IgE immunoblotting to dog epithelial SPT preparation (III)
In study III, the immunoblot analysis showed that dog-allergic patients had IgE reactivity
against allergens other than Can f 1 and Can f 2 in dog epithelial extract. The IgE reactivity
was mostly seen against the 18 kDa (60%), 40 kDa (44%) and 70 kDa (48%) molecules.
Further analysis of the 18kDa protein suggested that it is a new member of the lipocalin
family. The aminoterminal sequence (LPNVLTQVSGPWK) which exhibits no identity with
any known dog or other allergens, contains the triplet glysine-x-tryptophan which is
characteristic for the first structurally conserved region of lipocalins.
5.2.2 Human IgE responses measured by ELISA (III-IV)
The IgE reactivity of dog-, cow-, horse-, and mouse-allergic patients to dog rCan f 1 and 2,
cow rBos d 2, horse rEqu c 1 and mouse rMus m 1, respectively, was measured by indirect
ELISAs (Table 4). The prevalence of dog-allergic patients’ sensitization to Can f 1 was 44%
(III) and 42% (IV) and to Can f 2 20% (III) and 16% (IV).
A significant correlation was found between the IgE levels of dog-allergic patients and Can f
1 and Can f 2 (IV, r=0.514, p=0.003). The sensitization prevalence of horse-allergic patients
to Equ c 1 was 76%, whereas 66% of the mouse-allergic patients had specific IgE to Mus m 1.
Among the cow-allergic patients, 83% were sensitized to Bos d 2. All control subjects were
negative. The differences in the IgE levels between control subjects and allergic patients were
statistically significant (III, Fig. 4 and IV, Fig. 2).
 In study IV, the measurement of specific IgE levels to an endogenous lipocalin, rTL,
showed that seven out of 42 allergic patients had specific IgE to the protein (IV, Fig. 3). It is
noteworthy that six of the rTL IgE-positive patients were Can f 1 IgE-positive, while all seven
patients were dog-allergic (IV, Fig. 3). The rTL-specific IgE level of Can f 1-positive patients
differed significantly (p=0.014) from that of Can f 1-negative patients. Moreover, a high
correlation (r=0.81, p=0.007) was seen between the rCan f 1 and rTL-specific IgE levels of
Can f 1-allergic patients.
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Table 4. IgE and skin prick test reactivities of allergic patients
Frequency (n,(%)) of patients positive in
Skin prick test Immunoblotting ELISA study
Can f 1 13 (52) 13 (52) 11 (44)
13 (42)
III
IV
Can f 2  8 (32)  7 (28)   5 (20)
  5 (16)
III
IV
Equ c 1  11 (52)* 16 (76) IV
Mus m 1 10 (66) 10 (66) IV
Bos d 2 15 (83) IV
TL   7 (17) IV
Number of patients allergic to dog: 25 (III) 31 (IV), to horse: 21, to mouse: 15, to cow: 18,
total number of allergic patients 41 (IV).  * Determined with sera of 11 patients
5.2.3 Skin prick test reactivity to Can f 1 and Can f 2 and its association to IgE
 immunoblot and ELISA results (III)
In study III, the relationships were analysed for the results obtained with IgE immunoblotting,
IgE ELISA and SPT. Negative and positive SPT and immunoblotting results with Can f 1
showed perfect concordance (Table 5). The results between ELISA and immunoblot or SPT
were also highly concordant. As for the reactivity to Can f 2, the highest concordance was
obtained between the SPT and IgE immunoblotting results. The concordance between ELISA
and SPT results was lower than that between ELISA and immunoblot results.
Table 5. The concordances for positive and negative results between the results obtained with
SPTs, IgE-immunoblotting and IgE-ELISA
SPTs
?? coefficient)
Immunoblotting
?? coefficient)
Can f 1 Immunoblot 1.0 -
ELISA 0.88 0.88
Can f 2 Immunoblot 0.92 -
ELISA 0.75 0.82
P<0.001 in all analyses
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The magnitude of SPT reactions at 2.5µg/ml and the level of rCan f 1-specific IgE (all
subjects, n=36) exhibited a high correlation (r =0.82, P<0.001). The correlation for rCan f 2
was lower (r =0.66, P<0.001). The sizes of SPT reactions showed no difference between Can
f 1-single positive and Can f 1&Can f 2-positive patients. However, the results differed
significantly from those of the control and Can f 1-negative patients (III, Fig. 3). The SPT
results of the control subjects were negative.
 The sensitivity was highest (52%) in SPT with rCan f 1, but 44% for rCan f 1-specific IgE
measurements. The sensitivities in tests with rCan f 2 remained lower: 32% for SPT and 20%
for the IgE measurement.
5.2.4 Specific IgG and IgG-subclass responses of different mouse strains to Bos d 2 (I)
To examine the murine immune responses to natural Bos d 2, mouse strains with different H-
2 (i.e. murine MHC) haplotypes were immunized i.p. twice at two-week intervals with nBos d
2 (25µg/mouse) in alum. Out of the 6 mouse strains, only BALB/c mice clearly showed an
elevated level of nBos d 2-specific IgG (OD>1.9; I, Fig. 1). Although A.SW, B10.M and
CBA/s mice showed clearly lower levels of Bos d 2-specific IgG (OD<0.65) immunization
with tetanus toxoid (25µg/mouse) induced a high TT-specific IgG response (OD>2) in all the
mouse strains.
 The IgG subclass analysis of nBos d 2-immunized BALB/c mice (50µg/mouse) showed
that specific IgG1 levels in the serum were elevated after the second immunization. The Bos d
2-specific IgG1 levels increased up to the fourth immunization (I, Fig.2). In contrast, no
specific IgG2a was observed. When the mice were immunized with HEL or TT, the specific
IgG2a was detected after the second immunization.  The level of TT-specific IgG2a increased
up to the fourth immunization. In contrast to Bos d 2 and HEL immunizations, TT-specific
IgG1 was seen immediately after the first immunization (I, Fig. 2). After the second
immunization, the antibody-specific IgG1-levels differed statistically (P<0.05).
 When the BALB/c mice were immunized with recombinant Bos d 2 (50µg/mouse), low
levels of antigen specific IgG2a were detected after the second immunization (OD 0.17±0.04
(SEM)). The immunization with a higher dose of rBos d 2 (500µg/mouse) slightly increased
the Bos d 2-specific IgG2a level (OD 0.28±0.05 (SEM)). In parallel, Bos d 2-specific IgG1
levels tended to be higher with the high dose immunization than with the low dose
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immunization. However, the difference in the IgG2a or IgG1 levels between the groups with
high or low dose immunizations was not statistically significant (P>0.05 with both). As
illustrated in Fig.3 (I), the differences in IgG1/IgG2a-ratios between the control protein
groups (HEL, TT) and the low dose rBos d 2 group were statistically significant (P< 0.05).
5.3 Responses of murine spleen and lymph node cells to rBos d 2 (I)
5.3.1 Proliferative responses (I)
To examine proliferation responses of spleen cells, 6 different mouse strains were immunized
i.p. with 25 µg of nBos d 2/mouse in alum. In vitro responses of spleen cells with nBos d 2 at
50µg/ml turned out to be very low (stimulation indices <1.7, medium background range 600-
2900c.p.m.) after two immunizations. Additional immunizations, an increased dose of rBos d
2 (50µg/mouse), usage of CFA or IFA or an increase in the dose of rBos d 2 in vitro did not
enhance the spleen cell response of BALB/c, CBA/s or B57BL/6 mice (I, data not shown).
Comparison of the proliferative responses of spleen cells of rBos d 2, HEL or TT-immunized
BALB/c mice showed that the in vitro response induced by rBos d 2 was the weakest (I,
Fig.4). The second immunization increased the responses in all immunization groups,
although the increase in the response to rBos d 2 was negligible. The differences in
proliferative responses between rBos d 2, HEL and TT-immunized groups were statistically
significant after the second immunization (I, Fig.4).
 However, when the mice were immunized s.c. with rBos d 2 or HEL in CFA the
proliferative responses of BALB/c mice lymph node cells were observed to be stronger than
those of the spleen cells in i.p immunized mice, SI 3.5±0.7 (SEM) and 1.4±0.2 (SEM),
respectively.
5.3.2 Cytokine responses (I)
To characterize cytokine production of BALB/c mouse spleen cells, the mice were
immunized i.p. with 50mg of rBos d 2, HEL or TT /mouse in alum up to two times at a two-
week interval. After the first immunization, rBos d 2 induced only a weakly detectable level
of IL-4, which did not notably increase after the second immunization. The differences in IL-
4 production were statistically significant between rBos d 2 and the other immunization
groups (HEL and TT) after the second immunization (P<0.05), whereas the IL-5 production
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showed no statistical difference (P>0.05). Although TT and HEL were stronger inducers of
IL-2 than rBos d 2 (P<0.05), IL-2 production was very weak in all groups. IFN-g production
was not detected upon stimulation with the antigens. Con A stimulation induced substantial
secretion of the four cytokines in all groups.
 To verify the influence of the immunization protocol on the outcome of the response,
BALB/c mice were immunized s.c. with rBos d 2 and HEL in CFA. Immunization of the mice
with rBos d 2 s.c. increased the production of IL-4 and IFN-g of rBos d 2-stimulated lymph
node cells. On the other hand, the IL-4 and IL-5 responses of the cells in HEL immunized
mice were weaker than those of mice with i.p. immunization. No statistical differences were
seen between rBos d 2 and HEL in the production of IL-5 and IFN-g.
5.4 Immunodominant epitope of Bos d 2 (I-II)
5.4.1 Proliferative spleen and lymph node cell responses to the immunodominant epitope
 p127-142 (I-II)
The epitope mapping of Bos d 2 with overlapping 16mer peptides showed that the spleen cells
of BALB/c mice recognize one immunodominant epitope in Bos d 2 (I, Fig. 3), the p127-142.
The epitope is localized at the C-terminus of the protein and is almost identical to that
recognized by human T cells.  Proliferative responses of spleen cells from mice immunized
with p127-142 (100 mg/mouse) in IFA or CFA seemed to be stronger than those obtained with
alum as an adjuvant (I, Fig.6, P> 0.05). As observed with Bos d 2, the magnitude of
proliferative response to p127-142 stimulation was dependent on the cell type. Immunization
with p127-142 in CFA followed by in vitro stimulation of the lymph node cells with the
peptide, induced a stronger proliferative response than that with spleen cells. The stronger
proliferative response was observed with lymph node cells in spite of the ten-fold lower
immunization dose (10mg/mouse s.c. and 100 mg/mouse i.p.) (I, Table 4).
 In study II, the spleen cells of PBS-treated BALB/c mice or mice primed with database
search peptide (SP) were found to proliferate when stimulated with p127-142 (50 µM) (II,
Fig. 4, Fig. 5G, and data not shown). The phenomenon was further studied with BALB/c,
CBA and C57BL/6 mouse strains. In repeated experiments, the spleen cells from PBS-treated
BALB/c mice proliferated dose-dependently upon stimulation with the peptide in vitro (II,
Fig. 6). Interestingly, the spleen cells of PBS treated C57BL/6 mice recognized p127-142,
although this strain was observed to be a nonresponder to rBos d 2 in study I. CBA, a strain
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which was found to be a nonresponder to nBos d 2 in study I, did not mount any spleen cell
response to p127-142.
5.4.2 Cytokine responses of murine spleen and lymph node cells to p127-142 (I-II)
In the BALB/c mouse, the cytokine response to p127-142 varied depending on the
immunization route and the cells stimulated. The cytokine response of i.p. primed spleen cells
in BALB/c mice was of the Th2-type (I, Table 3, II, Fig.5B) regardless of the adjuvant. For
example, with alum as the adjuvant, IL-5 production was high (332±160 pg/ml), whereas IL-2
and IL-4 secretions were at a low level (2.3±1.0 U/ml and 7.8±1.5 pg/ml, respectively). No
IFN-g production was detected. In study II, in which cytokine production was measured by
ELISPOT, the cytokine profile upon stimulation with p127-142 was IL-4-dominated at low
stimulation doses (II, Fig.5B). The profile of p127-142 was more balanced at a stimulation
dose of 100µM.
 In contrast to spleen cells, lymph node cells from BALB/c mice immunized s.c. with CFA
as the adjuvant, mounted a Th1-type response with strong IFN-g production (I, Table 4,
734.8±231.1 pg/ml) and low level of IL-5 production (I, Table 4, 48.5±11.6 pg/ml). No IL-4
was observed.
5.4.3 Characteristics of the core region of p127-142 (I-II)
The epitope core sequence was estimated to be between E129 and V140
(EKYQQLNSERGV) with overlapping peptides (I). Additional analyses with truncated
peptides of p127-142 suggested that the critical amino acids for recognition by T cells of
BALB/c mouse were between K130 and G139 (II, Fig.2). The spleen cell responsiveness of
p127-142-primed mice was very sensitive to the deletion of the terminal amino acids of the
peptide. Removal of four amino acids from the N-terminus (including K130) or four from the
C-terminus (including G139) strongly decreased the proliferative response. Furthermore, the
response to a peptide truncated at both ends (K130-G139) remained at a background level.
 For further characterization of p127-142, the primed spleen cells were stimulated in vitro
with the alanine-substituted analogs of the peptide (II, Fig. 1). In the central part of the
peptide, the residues Q132, Q133, N135, E137 and R138 did tolerate notably less alanine or
other amino acid substitutions, classified as conservative or semiconservative, (Tangri et al.,
2001) (data not shown) suggesting the importance of these amino acids in T-cell recognition.
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Furthermore, the probable MHC anchor amino acids, Y131, L134, S136, and G139 (see
below), were less sensitive to substitution, since their replacement with conservative amino
acids did not abrogate the response.
 The MHC restriction of the immunodominant epitope was characterized with purified
spleen T cells and I-Ad or I-Ed-transfected fibroblasts as antigen presenting cells. I-Ad-
transfected cells were able to present the peptide to T cells more efficiently than were the I-
Ed-transfected cells (II, Fig. 3). This result was confirmed by measuring the binding of p127-
142 and its 34 analogs to I-Ad (II, Table 1) and I-Ed molecules (data not shown). The peptide
bound to I-Ad molecule, whereas no binding with the peptide was observed in the I-Ed
molecule. The binding results suggest that Y131 is the MHC anchor amino acid in position 1.
The amino acids in position 1 and 4 of the peptide are in accordance with the motif reported
for I-Ad molecule (Database Syfpeithi, http://www.syfpeithi.de/).
5.5 T-cell and IgE cross-reactivity of lipocalin proteins (II, IV)
5.5.1 Cross-reactivity of mouse spleen cells recognizing the immunodominant epitope
 (II)
To examine the potential cross-reactivity of p127-142-recognizing T cells, the spleen cells of
p127-142-primed BALB/c mice were stimulated in vitro with p127-142, database search
peptides SP1-SP9 or lipocalin peptides SP10-SP20 at 50 µM. Only SP3 (Bacillus subtilis) and
SP7 (Spiroplasma citri) were able to give rise to a proliferative response, albeit at a low level
(SI 2.4±0.3 and 2.1±0.2, respectively) compared to p127-142 (SI 11.8±2.5) (II, Fig.4). In
contrast to other SP-primed murine spleen cells, in vitro stimulation of the cells of SP7-
primed mice with p127-142 induced a strong cross-reactive response (Figs. 4 and 5D).
 For analyzing the capacity of different peptides to modulate the Th1-Th2 balance of an
immune response, the IFN-g and IL-4 secretion induced by SP7 and SP12 (lipocalin allergen
peptide from Equ c 1) was compared with that induced by p127-142 (Fig. 5). ELISPOT
analysis revealed that the cytokine responses to p127-142 and SP12 induced a similar IL-4-
dominated cytokine profile (II, Figs. 5B and 5H), although their capacity to induce
lymphocyte proliferation was different (II, Figs. 5A and 5G). SP7 induced a Th0-type
response and elicited the strongest proliferation (II, Figs.5D and 5E).
 The peptides p127-142 and SP7 could prime spleen cells reciprocally for cytokine
production (II, Figs. 5C and 5F). The spleen cells of p127-142 primed mice stimulated in vitro
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with SP7, mounted a Th0-type response (Fig. 5C). Whereas, the stimulation of spleen cells
from SP7-primed mice in vitro with p127-142 resulted in a IL-4 dominated response (Fig.
5F).
5.5.2 Human IgE cross-reactivity among lipocalin proteins (IV)
The IgE cross-reactivity among lipocalins was determined by indirect ELISAs. Three to five
sera with strong reactivity to pure recombinant allergens were pooled and preincubated with
the allergens, rTL or the control proteins before ELISA assays with lipocalin-coated plates.
The cross-reactivity was seen dose-dependently with four serum pools specific to rCan f 1,
rTL, rCan f 2 and rMus m 1 (IV, Fig. 4). The preincubation of the rCan f 1-specific serum
pool with rTL could inhibit IgE binding to rCan f 1 (IV, Fig. 4A). Reciprocally, rCan f 1 was
able to inhibit IgE binding of the rTL-positive serum pool to rTL (IV, Fig. 4B). Interestingly,
in both groups, rCan f 1 was a more efficient inhibitor of specific IgE binding than rTL. The
concentration of rCan f 1 needed for 50% inhibition (IC50) of Can f 1-specific IgE binding
was about 400-fold lower than that of rTL. Furthermore, the IC50 of rCan f 1 for the inhibition
of rTL-specific IgE was 100-fold lower than IC50 of rTL.
 The IgE cross-reactivities between rCan f 2 and rCan f 1 and between rMus m 1 and rEqu c
were partial. The preincubation of the rCan f 2-specific serum pool with rCan f 1 inhibited
IgE binding to rCan f 2 very weakly (IC50?200µg/ml, Fig. 4C), whereas rCan f 2 could not
prevent the binding of specific IgE to rCan f 1 at all. Furthermore, the preincubation of rMus
m 1-specific serum pool with rEqu c 1 inhibited the binding of IgE to rMus m 1 (Fig. 4D).
However, IC50 was over 400-fold higher with rEqu c 1 than that of rMus m 1. In contrast,
rMus m 1 could not inhibit the specific IgE binding to rEqu c 1. No IgE cross-reactivities
were seen between Bos d 2 and other lipocalin proteins (data not shown).
5.6 Modelling of the IgE-cross-reactive site (IV)
The sequence identities between lipocalin proteins are shown in Table 6 (IV, Fig.5). The
sequence alignments of the lipocalins with IgE cross-reactivity showed that identical amino
acids form short continuous segments which were located quite evenly in the sequence and
consequently in the structure (IV, Fig. 6). Equally located, similar segments in secondary
65
structural elements and in loops pointed to several potential areas for IgE cross-reactivity, for
example, in Equ c 1 and rMus m 1.
 Since the crystallographic three-dimensional structure of Can f 1 has not been solved, it is
not possible to compare the identical residues on the surface of Can f 1 and TL. Nevertheless,
the mapping of identical residues on the surfaces of Equ c 1 and Mus m 1 (Fig. 6) showed
quite an even distribution. The largest similar area (and putative epitope) on the surface can
be found around the two-fold axis containing the N-terminus of strand C and the C-terminus
of strand D of the monomers. It is noteworthy that according to the amino acid sequences (IV,
Fig. 5), these segments in strands C and D also have similarities in the IgE cross-reacting pair
TL-Can f 1.
Table 6. The sequence identities between lipocalin proteins. The cross-reactive pairs are
indicated with grey boxes.
* the SIB BLAST network service at the Swiss Institute of Bioinformatics, April 5, 2007)
Sequence identity (%)*
 3-D
structure Can f 1 Can f 2 TL Equ c 1 Mus m 1 Bos d 2
Can f 1 - 100 23 61 28 20 -
Can f 2 - 100 19 25 27 -
TL +  100 26 20 18
Equ c 1 + 100 46 32
Mus m 1 + 100 28
Bos d 2 + 100
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6. DISCUSSION
6.1 Humoral immune responses to lipocalins (I, III-IV)
6.1.1 Murine humoral immune responses of mice to Bos d 2 (I)
Several studies have shown that despite the strong IgE-inducing capacity of lipocalin
allergens (Zeiler et al., 1999; Smith et al., 2004), they generally induce weak Th2-dominated
cellular responses (Zeiler et al., 1999; Immonen et al., 2003; Jeal et al., 2004; Immonen et al.,
2007). Therefore, it has been hypothesized that strong IgE and weak cellular immune
responses to lipocalins may be associated with their allergenicity (Virtanen et al., 1999). In
study I, Bos d 2-specific cellular and antibody responses were determined with six mouse
strains of different haplotypes, including the BALB/c mouse. Of the six mouse strains, only
BALB/c mice showed high nBos d 2-specific IgG levels after i.p. immunization. Repeated i.p.
immunizations with nBos d 2 resulted in an increased IgG1 response but failed to induce an
IgG2a response. This finding is in contrast to observations with HEL and TT. The high IgG1
and low IgG2a response of BALB/c mice to rBos d 2 pointed to a Th2-deviation of response,
since the synthesis of IgG1 is one of the markers of the Th2 response, and IgG2a the marker
of the Th1 response (Rosenkrands et al., 2005; Gizzarelli et al., 2006; Gomez et al., 2007).
Furthermore, rBos d 2 induced weak specific IgG1 and IgG2a responses compared to the
control antigens. Since the proliferative responses (see below) were also weak, it appears that
Bos d 2 is a weak immunogen for several mouse strains.  It also seems that the murine
responses against Bos d 2 resemble those observed in humans.
6.1.2 Human IgE responses to lipocalin allergens (III-IV)
The use of recombinant allergens for the diagnostics and immunotherapy of allergy has many
advantages over allergen extracts (Chapman et al., 2000). The key advantage of recombinant
allergens is their straightforward standardization. Importantly, yeasts such as Pichia pastoris,
have been shown to produce bioactive, fully immunoreactive recombinant proteins in large
quantities (Rouvinen et al., 1999; Daly et al., 2005; Macauley-Patrick et al., 2005). Therefore,
all our recombinant proteins were chosen to be produced in Pichia pastoris yeast (Studies I,
III-IV).
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 Mass-spectrometric analyses confirmed that the sequences of the HPLC-purified
recombinant proteins were correct. Skin prick tests with the lipocalin allergens and lipocalin-
specific IgE-reactivity in immunoblotting, immunoblot inhibition and in ELISA showed that
the recombinant proteins were immunologically functional (III-IV).
 In studies III-IV, the prevalence of Can f 1-specific IgE was found to be lower than that
reported by Konieczny et al. (1997). Levels of detected Can f 1-specific IgE ranged from 44%
(III) to 42% (IV) of the sera in dog-allergic patients, whereas 75% of the patients had Can f 1-
specific IgE in the study of Konieczny et al. (1997). Detection by immunoblotting increased
the prevalence of IgE reactivity to 52% (study III). The prevalence of Can f 2-specific IgE in
study III was similar, and in study IV slightly lower than that detected by Konieczny et al.
(Konieczny et al., 1997). One explanation for the difference between the studies in the
prevalence of IgE reactivity to Can f 1 and Can f 2 may be the different methods used to
define a positive reaction. In the study III, the cut-off value was the mean OD of the control
subjects + 3 SD at a dilution 1:10. In contrast, the study of Konieczny et al. defined a positive
sera as those that gave an OD of at least double the uncoated plate background at a dilution of
1:4 (Konieczny et al., 1997).
 It can be speculated that this discrepancy can be attributed to differences in the selection
and demographics of the patients. On the one hand, the prevalence of allergic diseases (Asher
et al., 2006) and the HLA allele distribution (Partanen et al., 1997) in Finland do not differ
from that in most Western European countries. On the other hand, 100 % of birch-allergic
patients in Finland and 98% in Sweden were found to be IgE positive to Bet v 1, whereas
62% and 65% of the patients in Italy and Switzerland, respectively, had Bet v 1-specific IgE
(Moverare et al. 2002b). Moreover, in allergy to cherries, major differences have been
observed across Europe in the sensitization pattern and prevalence of the systemic reaction
(Reuter et al., 2006). Spanish patients were almost exclusively sensitized to Pru av 3 (91%),
whereas 96% of the German patients were sensitized to Pru av 1 but only 11% to Pru av 3
(Reuter et al., 2006). Therefore, if recombinant allergens are used for allergy diagnostics or
immununotherapy, it is important to take into consideration  geographic and demographic
factors.
 Interestingly, IgE to human tear lipocalin (TL) was observed in the sera from seven out of
42 dog-allergic patients in study IV. It has been suggested that autoreactive IgE production
could be induced by a cross-reactive exogenous allergen (Budde et al., 2002; Aichberger et
al., 2005). This view is also in keeping with our results. TL-specific IgE levels of the patients
were extremely low, with all but one of the patients with TL-specific IgE found to be Can f 1
68
positive. It seems, therefore, reasonable to suppose that TL-specific IgE is Can f 1-specific
with cross-reactivity to TL. This is also supported by the finding in inhibition experiments
that rCan f 1 was a more potent inhibitor of both Can f 1 and TL-specific IgE binding than
TL.
6.1.3 Use of recombinant Can f 1 and Can f 2 for the diagnostics of dog allergy (III)
Recombinant allergens have been shown to improve sensitivity over extract-based diagnostic
tests. For example, the mix of cherry allergens rPru av 1, 3 and 4 had a sensitivity of 95%
compared with 65% for cherry extract in ImmunoCAP tests (Reuter et al., 2006). One aim in
study III was to evaluate the applicability of recombinant Can f 1 and Can f 2 for the
diagnostics of dog allergy. Although, the recombinant dog allergens Can f 1 and Can f 2 were
found to have high specificity (100%) for the diagnostics of dog allergy, additional allergens
should be involved due to the poor sensitivity of the allergens. For example, the sensitivity of
Can f 1 in ELISA was only 44%. Furthermore, it should be noted that the usage of Can f 2
does not increase the sensitivity of diagnostics for dog allergy, since all patients who
recognized Can f 2 also recognized Can f 1.
 Since the prevalence of Can f 1 and Can f 2-specific IgE reactivity among dog-allergic
patients was relatively low, it seems that other dog allergens in addition to Can f 1 and Can f 2
are important in sensitization to dogs. One interesting candidate for a recombinant allergen
mixture for the diagnostics of dog allergy would be the 18 kDa protein found in the dog SPT
preparation. This previously unknown protein was recognized more frequently than Can f 1
by allergic patients. Furthermore, it is of special interest since the amino terminus of the
protein contains a lipocalin-specific sequence motif (Flower et al., 2000), suggesting it as a
new member in the lipocalin family. The protein was recently named Can f 4 by IUIS.
 Serum albumin, Can f 3, is a protein with a molecular mass of approximately 70 kDa
(Pandjaitan et al., 2000). Can f 3 would be useful for the diagnostics of dog allergy since it
was also recognized by a considerable number of patients. The use of Can f 1, Can f 3, and
Can f 4 in a mixture for diagnostics of dog allergy would increase the sensitivity to ~70%.
 The results do not indicate which allergens are included in the commercial SPT test
preparation that 28% of the allergic patients recognized in SPT but were not visualized in
immunoblotting. It can be speculated that a natural SPT preparation contains some allergen
determinants that could have deteriorated during the SDS-PAGE treatment and
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immunoblotting and were therefore not recognized. On the other hand, the patients may
exhibit low-level reactivity to more than one dog allergen, thus yielding positivity in SPT.
6.2 Murine cellular immune responses to lipocalins (I-II)
To elucidate murine cellular immune responses to the bovine lipocalin allergen Bos d 2, the
proliferative and cytokine responses of six mouse strains were examined (I). The cellular
responses with all six mouse strains against Bos d 2 immunized i.p. were weak. The results
resemble those with human T cells against lipocalin allergens, including Bos d 2 (Zeiler et al.,
1999; Immonen et al., 2003; Jeal et al., 2004; Immonen et al., 2007). The cytokine secretion
by  spleen cells of i.p. immunized BALB/c mice showed that Bos d 2 and the control proteins
HEL and TT all induced a Th2-type response with moderate or high IL-4 and IL-5 levels and
without detected IFN-?. The result may be attributed to the characteristics of the BALB/c
mouse which tends to favor Th2-type responses (Rosenkrands et al., 2005; Theiner et al.,
2006). However, when the mice were immunized s.c. with Bos d 2 and HEL in CFA, the
responses were more of the Th1 type. Therefore, a more probable explanation for the Th2-
type cytokine profile with the Bos d 2 and the control antigen groups could be the influence of
the immunization route (Yip et al., 1999) and type of adjuvant used (Comoy et al., 1998; Yip
et al., 1999)
 Zeiler et al. have previously shown that human T cells recognize one immunodominant
epitope in Bos d 2 (Zeiler et al., 1999). The peptide p127-142 containing the
immunodominant epitope was recognized by all cow dust-asthmatic patients (Zeiler et al.,
1999). Futhermore, the peptide was also found to be immunodominant in the BALB/c mouse.
For example, studies with allergens to house dust mite, Der p 1 (Jarman et al., 2005), and
mugwort pollen, Art v 1 (Jahn-Schmid et al., 2002), suggest that the immunodominant
epitopes of these allergens account for the Th2 dominance of the immune response.
Furthermore, all the human T-cell clones to the immunodominant epitope of Bos d 2 were
classified as Th0-like or Th2-like clones (Zeiler et al., 1999). Therefore, the role of p127-142
in determining the quality of immune response against Bos d 2 was studied in the BALB/c
mouse in more detail (I-II). Although, it turned out that the quality of the response against
p127-142 was connected to the immunization route, the type of adjuvant and the type of cell
(spleen or lymph node cell), the response to the peptide tended to be more of the Th2 type. In
addition, the proliferative response of the spleen cells of the BALB/c mouse to the
immunodominant peptide seemed to be as weak as the response to the whole protein.
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Interestingly, the other lipocalin peptide SP12 from horse also induced a low proliferative
response with IL-4-dominant cytokine production (study II). In contrast, bacterial peptide SP7
from Spiroplasma citri elicited a strong proliferative response with a more balanced cytokine
profile. These results are in keeping with those findings suggesting that a weak stimulation
through the T-cell receptor (Janssen et al., 2000; Brogdon et al., 2002) favors the Th2-biased
cellular response and may be one factor determining the allergenic capacity of a protein
(Kinnunen et al., 2003).
 The cellular immune responses of the spleen cells of the BALB/c mouse to p127-142
resembled those of a human T-cell clone (Kinnunen et al., 2003). The minimal core region of
the peptide was close to that recognized by the clone (Kinnunen et al., 2003). Moreover, the
critical amino acids for T-cell recognition by the murine spleen cells and the human T-cell
clone (Kinnunen et al., 2003) colocalized closely. Since recognition of p127-142 by the
BALB/c mouse resembles that with a human T-cell clone, the BALB/c mouse could provide a
useful tool for peptide based immunotherapy experiments.
 Since human T cells also recognize an area corresponding to p127-142 in Rat n 1 (Jeal et
al., 2004), Can f 1 (Immonen et al., 2003) and Equ c 1 (Immonen et al., 2007), the recognition
of the areas corresponding to these in lipocalins was examined in the BALB/c mouse. Despite
colocalization of human T-cell epitopes, it was found that of the 11 lipocalin peptides only
p127-142 and the corresponding region in Equ c 1, SP12, were immunogenic for BALB/c
mice. Is has recently been shown by Immonen et al. that the immunodominant epitope of Equ
c 1 localizes adjacent to p127-142 of Bos d 2 (Immonen et al., 2007).
6.3 Cross-reactivity among lipocalin proteins (II, IV)
6.3.1 T-cell cross-reactivity among lipocalin proteins (II)
The T-cell and IgE cross-reactivities of lipocalin allergens are poorly known. Immonen et al.
have recently reported that specific T-cell lines induced with p107-122 of Can f 1 cross-
reacted with a homologous peptide of human tear lipocalin (Immonen et al., 2007). To
examine T-cell cross-reactivity among p127-142 and 20 database search peptides including
11 lipocalin peptides, BALB/c mice were primed with the peptides. The spleen cells of
BALB/c mice primed with p127-142 did not exhibit T-cell cross-reactivity among the
lipocalin peptides. This was likely due to low sequence identity among the peptides
(Kinnunen et al., 2003). The p127-142 primed spleen cells, however, did cross-react with a
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homologous bacterial peptide SP7 (Spiroplasma citri). Interestingly, the sequences of p127-
142 and SP7 were almost identical in the core reqion of p127-142, but not in the N- or C-
termini. Molecular mimicry has been suggested as a possible link between some autoimmune
diseases and infections. For example, several type 1 diabetes-related HLA molecules have
been shown to exhibit high binding affinity for the peptide of the Coxsackie virus B4 (Ellis et
al., 2005). Moreover, T cells from MS patients recognizing peptide MBP(93-105) were
observed to cross-react and be activated with a peptide identical to a segments of a protein
from human herpervirus-6 (Tejada-Simon et al., 2003). Furthermore, T-cell cross-reactivity
between an autoantigen and an exogenous allergen has been suggested to be involved in the
induction and maintenance of severe forms of allergy (Bünder et al., 2004). The result that
p127-142 and SP7 are T-cell cross-reactive supports the view that a T cell-response can be
primed with a peptide from an unrelated protein.
 In severe atopic dermatitis, it has been suggested that the molecular mimicry of a human
homolog with a microbial protein (Crameri et al., 1996; Schmid-Grendelmeier et al., 2005)
can exacerbate the disease shifting the Th2 response to become more of the Th1 type.
However, deviation in the T-cell response can also be useful for allergen immunotherapy. For
example, a Th1 skewing peptide analog of a dominant allergen epitope has been observed to
modulate favourably the polarized Th2 response in vitro and in vivo in a murine asthma
model (Janssen et al., 2000). Furthermore, it has been speculated that novel cross-reactive T-
cell populations induced by peptide analogs can have therapeutic immunomodulatory effects
in vivo, for example, through bystander suppression (Kinnunen et al., 2007). In human
autoimmune diseases, trials with Th2-skewing altered peptide ligands have already been
performed (Raz et al., 2001; Kim et al., 2002; Alleva et al., 2006).
 It was also found that p127-142 was able to induce the proliferation of spleen cells in naïve
BALB/c and C57BL/6 mice in vitro (II). This is interesting, since the C57BL/6 mouse was
found to be a nonresponder to Bos d 2 in study I. The influence of endotoxins can be excluded
since the purity of the peptide was confirmed by mass spectrometry. As the phenomenon was
observed repeatedly with the cells of the BALB/c mouse in two independently synthesized
peptide lots but not with other peptides, it can be assumed that the phenomenon is related to
the immunodominance of p127-142. This view is supported by several autoimmune studies.
In EAE, the immunodominant epitope of myelin proteolipid protein (PLP) is recognized by
the unprimed T cells of SJL mice (Anderson et al., 2000). Moreover, the immunodominant
epitope of myelin basic protein (MBP) (Tejada-Simon et al., 2001) and several peptides of
myelin oligodendrocyte glycoprotein (MOG) have been found to be recognized by human T
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cells from healthy individuals  (Van der Aa et al., 2003). In SJL mice, escape from central
tolerance, combined with peripheral expansion by cross-reactive antigen(s) was thought to be
responsible for the high frequency of PLP 139-151-reactive T cells (Anderson et al., 2000).
On the other hand, it can be speculated that the mice in study IV might have been primed with
cross-reactive environmental lipocalins, such as lipocalins of rat and rabbit, in the laboratory
animal facility. However, on the basis of the results of study IV it is not possible to conclude
whether the response of spleen cells of naïve BALB/c mice upon stimulation with p127-142
resulted from the proliferation of naïve or primed T cells.
6.3.2 IgE cross-reactivity among lipocalin proteins (IV)
The IgE cross-reactivities of animal allergens are poorly known, the exception being serum
albumins. Taking into account the importance of animal-derived proteins as respiratory
sensitizers, it is surprising that IgE cross-reactivity among these allergens has only been
studied quite recently. In study IV, the aim was to characterize the cross-reactivity among five
lipocalin allergens and one human lipocalin. Four out of the six studied lipocalins showed
human IgE cross-reactivity, including human tear lipocalin.
 T-cell cross-reactivity is known to be due to a high sequential similarity. However, the
situation with B-cell cross-reactivity is different. IgE-binding epitopes, in contrast to T-cell
epitopes, are mainly conformational (Limacher et al., 2007). In general, it seems that IgE
cross-reactivity, for example, with pollen allergens mainly takes place when the sequence
similarity approaches at least 50% (Radauer et al., 2006a). However, recent studies with
phylogenetically conserved allergenic proteins suggest that high structural similarity may be
more important than high similarity at the sequence level (Fluckiger et al., 2002; Jenkins et
al., 2005; Sankian et al., 2005). Our results (study IV) support this view since cross-reactivity
was also seen between Can f 1 and Can f 2, the sequence identity of which was only 23%.
 In addition to sequence similarity, the so-called cross-reactive carbohydrate determinants
(CCD) are know to be involved in the IgE cross-reactivity of plant and insect-derived
glycoproteins (van Ree et al., 2000). However, since Mus m 1 and TL are nonglycosylated, it
is reasonable to assume that the cross-reactivity between Mus m 1 and Equ c 1 as well as
between TL and Can f 1 is due to a sequential or structural similarity. Futhermore, the
sequence alignment and 3-D modeling of Equ c 1 and Mus m 1 pointed to one large similar
area on the surface of these proteins. Therefore, it is conceivable that the cross-reactive
epitope could localize there. The IgE cross-reactivity between glycosylated Can f 2 and
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putatively glycosylated Can f 1 is also likely caused by a sequence or structural similarity
since it has been observed with the allergens produced in E.coli, as well (Kamata et al., 2007).
  The cross-reactivity between Mus m 1 and Equ c 1 was found to be partial because Equ c
1 inhibited Mus m 1-specific IgE binding, whereas Mus m 1 could not inhibit the binding of
Equ c 1-specific IgE. The respective phenomenon was also observed in the inhibition of Can f
1 and Can f 2-specific IgE-binding. When partially inhibited, allergen-specific IgE points to
common and unique epitopes between the allergens. Moreover, the cross-reactivity between
Can f 1 and TL was also partial. Although both of the allergens were able to inhibit each
others IgE binding, the inhibitory capacity of Can f 1 was clearly stronger. The situation is
similar with the birch allergen Bet v 1, which is capable of inhibiting IgE binding to an apple
allergen, Mal d 1, in a similar or even better way than Mal d 1 itself (Vanek-Krebitz et al.,
1995; Kinaciyan et al., 2007). Mal d 1 can only partially inhibit IgE binding to Bet v 1.
 The cross-reactivity between Can f 1 and TL is of special interest since TL is an
endogenous lipocalin. Cross-reactivities by autoreactive IgE among environmental allergens
have especially been described in severe atopies (Aichberger et al., 2005; Limacher et al.,
2007). It can be speculated that endogenous proteins that are IgE cross-reactive with
exogenous proteins may have a role in the regulation or tolerization of an allergic immune
response, e.g., through indoleamine 2,3-dioxygenase (IDO). The activation of IDO via the
high affinity IgE receptor (FceRI) may be part of the mechanism that suppresses unwanted T-
cell responses (von Bubnoff et al., 2003). FceRI has been reported to be, for example, highly
expressed on the surface of different subsets of dendritic cells in atopic (Allam et al., 2003;
Foster et al., 2003) and nonatopic patients (Allam et al., 2003). Several reports have shown
that dendritic cells can inhibit T-cell proliferation (Mellor et al., 2004) and tolerize the Th2
responses both in vitro and in vivo through the induction of IDO (von Bubnoff et al., 2003;
Gordon et al., 2005).
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7. CONCLUSIONS
The current study had three different aims. The first aim was to elucidate the allergenic
properties of Bos d 2 and the impact of MHC haplotype on the response against Bos d 2 in a
mouse model.Second, since the IgE cross-reactivity among lipocalin allergens is poorly
known, cross-reactivity was examined with five animal-derived lipocalin allergens and one
endogenous lipocalin. The third aim was to study the suitability of recombinant dog allergens,
Can f 1 and Can f 2, for the diagnostics of dog allergy.
 The major respiratory bovine allergen Bos d 2 was found to be a weak immunogen in six
different mouse strains. Only the BALB/c mouse mounted a distinct humoral response to Bos
d 2. Consistent with recognition by humans, BALB/c mice recognized one immunodominant
epitope in Bos d 2. Recognition of the immunodominant epitope peptide p127-142 closely
resembled that with human T cells. The p127-142 induced a Th2-type response in the
BALB/c mouse. Interestingly, p127-142 was also recognized by naïve spleen cells of this
mouse strain. It can be speculated that the phenomenon is related to the immunodominance of
p127-142. On the other hand, reciprocal induction of the cytokine responses by p127-142 and
a bacterial peptide from Spiroplasma citri (SP7) implies that modified allergen peptides can
skew the phenotype of primed T cells. Furthermore, the finding points to the possibility that
the Th2-type response can be primed with an unrelated protein or with a homolog of an
allergen. This phenomenon may open prospects for allergen immunotherapy.
 Four of the five lipocalin allergens and one human endogenous lipocalin were shown to be
IgE cross-reactive. Since the sequence identities among the cross-reactive proteins were
comparatively low (23-61%), it can be assumed that the phenomenon is partially caused by
the similarity of the three-dimensional structures within the proteins. Whether the cross-
reactivity among lipocalin allergens has clinical implications needs to be further elucidated.
The cross-reactivity between the major dog allergen Can f 1 and human tear lipocalin, on the
other hand, raises the question as to whether cross-reactivity between endogenous proteins
and environmental allergens could be implicated in the regulation or tolerization of an allergic
response.
 Finally, the immunologic activity of recombinant dog allergens Can f 1 and Can f 2 were
shown to be comparable to those with natural allergens. However, the sensitivity of the
allergens was insufficient for dog-allergy diagnostics. It seems that other dog allergens in
addition to Can f 1 and Can f 2 are important for sensitization to dogs. A new 18 kDa
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allergen, Can f 4, was preliminarily characterized in the dog epithelial preparation. Can f 4
was recognized by 60% of the dog-allergic patients, thus more frequently than their
recognition of Can f 1. Amino-terminal sequencing suggested that Can f 4 is a new member in
the lipocalin family. Highly sensitive diagnostics of dog allergy will require other dog
allergens in addition to Can f 1. These allergens could include, for example, dog albumin, Can
f 3, and the new lipocalin allergen Can f 4.
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